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Abstract
A Novel Antimicrobial Drug Discovery Approach for the Periodontal
Pathogen Porphyromonas gingivalis
By: Victoria N. Stone
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2015
Advisor: Ping Xu, Ph.D.
Professor, Philips Institute of Oral Health Research, School of Dentistry
Affiliate Associate Professor, Department of Microbiology and Immunology

The human body is colonized by more than 100 trillion microbes which make up an
essential part of the body and plays a significant role in health. We now know the over
use and misuse of broad-spectrum antibiotics can disrupt this microbiome contributing to
the onset of disease and runs the risk of promoting antibiotic resistance. With antibiotic
research still on the decline, new strategies are greatly needed to combat emerging
pathogens while maintaining a healthy microbiome. We therefore set out to present a
novel species-selective antimicrobial drug discovery strategy.
Disruption of the homeostasis within the oral cavity can trigger the onset of one of
the most common bacterial infections, periodontal disease. Even though the oral cavity is
one of the most diverse sites on the human body, the Gram-negative colonizer,
Porphyromonas gingivalis has long been considered a key player in the initiation of
periodontitis, suggesting the potential for novel narrow-spectrum therapeutics. By
targeting key pathogens, it may be possible to treat periodontitis while allowing for the
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recolonization of the beneficial, healthy flora. Therefore, we set out to use P. gingivalis
and periodontal disease as a model for pathogen-specific antimicrobial drug discovery.
In this study we present a unique approach to predict essential gene targets selective for
the periodontal pathogen within the oral environment. Using our knowledge of metabolic
networks and essential genes we identified a “druggable” essential target, mesodiaminopimelate dehydrogenase, which is found in a limited number of species. This
enzyme, meso-diaminopimelate dehydrogenase from P. gingivalis, was first expressed
and purified, then characterized for enzymatic inhibitor screening studies. We then
applied a computer-based drug discovery method, combining pharmacophore models,
high-throughput virtual screening and molecular docking. Utilizing the ZINC database
we virtually screened over 9 million small-molecules to identify several potential targetspecific inhibitors. Finally, we used target-based and whole-cell based biochemical
screening to assess in vitro activity. We conclude that the establishment of this target and
screening strategy provides a framework for the future development of new
antimicrobials and drug discovery.

xv

Introduction
I.

The Oral Microbiome

The term “microbiome” was coined by Joshua Lederberg describing “the ecological community
of commensal, symbiotic, and pathogenic microorganisms that literally share our body space” [1,
2]. The start of the microbiome era resulted in the question of how commensal microorganisms
contribute to human health and disease and sparked new areas of research. This directly led to
the NIH-sponsored Human Microbiome Project. We now know that microbes outnumber our
cells 10 to 1, making bacteria an important component of the human body. Through this project
it was discovered the oral cavity is one of the most complex and diverse sites [3], containing up
to 1000 phylotypes composed of viruses, protozoa, fungi, archaea and bacteria. However, since
many oral bacteria have yet to be cultured, the number may be even higher [1, 4]. While the
functional role of oral colonizers is not completely understood, studies indicate this area of the
microbiome plays a role in maintaining oral health. For one, the occupation by commensal oral
bacteria prevent the colonization of pathogens, a phenomenon known as colonization resistance
[5]. Commensal bacteria occupy the niche, limiting the available space and preventing the
establishment of foreign colonizers. As an indirect mechanism of colonization resistance,
commensal oral colonizers can produce antagonistic substances against pathogenic species [4, 6].
For example, many streptococcal species can synthesize inhibitory substances that prevent
colonization of other species. Streptococcus sanguinis produces hydrogen peroxide, which can
inhibit the growth of methicillin-resistant Staphylococcus aureus [7] and Streptococcus mutans, a
major contributor to dental caries [8]. Interestingly, studies also show the oral microbiome plays
a functional role in systemic health. Inorganic nitrate obtained through the diet is reduced to
1

nitrite within the oral cavity, absorbed into the bloodstream and then converted to nitric oxide.
This is beneficial, as metabolic studies show nitric oxide is important for maintaining
cardiovascular health through improved mitochondrial function and reduced blood pressure [9].
Petersson et al. linked oral bacteria to this metabolic role by noting the use of antimicrobial
mouthwash attenuated the nitrate reduction and abolished the associated decrease in blood
pressure [10].
Dental plaque. How is the complex oral microbiome established? The bacteria have the ability
to colonize the hard and soft surfaces (e.g., teeth, surfaces of the tongue, and epithelium) of the
oral cavity to form biofilms, more commonly known as dental plaque. Oral biofilms are
polymicrobial 3D structures composed of proteins, polysaccharides, nucleic acids, salts and cells
allowing for microbial interactions and cell-cell communication. It also provides the population
with nutrients, protection from antibiotics and other environmental threats [11, 12]. The
development of dental plaque is a systematic process occurring through five stages [12]. The first
stage begins almost immediately following brushing. The tooth surface obtains a coating of
glycoprotein deposits derived from saliva called the acquired pellicle. Through interactions with
cell surface structures, the pellicle mediates the initial bacterial attachment. It can be 1-20 layers
thick and within a clinically healthy cavity is composed of Gram-positive cocci, mainly of the
streptococcus species [13, 14]. These early colonizers are aerobes or facultative anaerobes as
they are able to tolerate the higher oxygen levels present [14, 15]. The second stage involves a
stronger attachment of the bacteria to the tooth surface. Following initial attachment to the
pellicle, weak, long-ranged interactions are formed that allows the bacteria to reverse the
attachment to the pellicle and tooth surface. Stronger short-range, irreversible attachments
between structures on the bacterial cell surface and the complementary receptors on the pellicle
2

are then formed [15]. The third step involves adhesion and aggregation of later colonizers to
previously attached early colonizers. Inter-bacterial adhesion-receptor interactions are initiated,
resulting in the diversification of the biofilm [13], as well as generating synergistic and
antagonistic interactions between species [15]. Fourth is the multiplication of the colonized
bacteria; this step involves cell division of colonized bacteria and expansion of the biofilm into a
complex 3D environment. Polymer composed of soluble and insoluble glucans is produced
forming the extracellular matrix. This matrix provides structural integrity and retains nutrients
within the biofilm. At this stage the biofilm is around 100-300 layers thick, generating an oxygen
depleted environment that allows for an increase in the number of Gram-negative anaerobic
bacteria [14, 16]. Last is active detachment. In response to environmental cues, the biofilm can
detach from the surface, disperse and colonize at different locations [15].
Periodontal disease. Typically, with proper oral hygiene, the oral microbiome exists in a
beneficial or benign state. However, ecological changes in the oral cavity can alter the
environment, shifting the dominant species from Gram-positive facultative anaerobes to Gramnegative anaerobes. The resulting change in the environment can lead to a major health concern
within the oral cavity known as periodontal disease [12]. Periodontal disease refers to a group of
chronic inflammatory processes that affect the gingival tissue and surrounding tooth supporting
structures [17]. Periodontal disease is a progressive disease that occurs in distinct stages.
Gingivitis, the most common form, is the early non-destructive stage, which is composed of the
initial, early and established lesion stages. It is reversible with proper cleaning and maintenance;
however, without treatment gingivitis may progress into a more chronic infection. The advanced
lesion stage marks the transition from gingivitis to periodontitis, the non-reversible destructive
form. Periodontitis is characterized by severe inflammation, plaque calcification, bone
3

resorption, and tooth loss [18]. During the early lesion stages of the infection, within 2-10 days,
accumulation of dental plaque triggers the host innate immune response where resident mast
cells produce histamine causing the endothelium to release IL-8 [19, 20]. Additionally,
macrophages recognize pathogen-associated molecular patterns (i.e., peptidoglycan,
lipopolysaccharide and foreign DNA) through toll-like receptors (TLRs), triggering the uptake of
the bacteria through phagocytosis and the release of cytokines such as IL-1β, IL-6 and TNF-α.
The release of these pro-inflammatory cytokines cause vascular dilation of blood vessels,
increasing permeability and blood flow. This also leads to the expression of adhesin molecules
on the endothelium surface, aiding in the recruitment and sticking of polymorphonuclear
neutrophils (PMNs) and activation of complement [21]. PMNs migrate to the epithelium and
gingival crevice releasing more IL-8, amplifying inflammation. However, the PMNs are unable
to phagocytose the bacteria, which are now associated within a thick biofilm. After
approximately 2-3 weeks of biofilm accumulation, antigen-presenting cells begin to stimulate
naïve T-cells. At this stage if T-cells have not eliminated the bacteria, an established lesion is set.
This stage is defined by B-cell activation to plasma cells [20, 21]. Th2 cells activate B-cells and
conversion of plasma cells leads to the secretion of antibodies. CD4+ T-cells continue to secrete
cytokines contributing to collagen degradation and inflammation [21]. At this point, if the
infection is not cleared, gingivitis progresses into periodontitis, corresponding to the advanced
lesion stage and marked by severe collagen degradation. The formation of deep periodontal
pockets allows for the migration of the biofilm, increased production of pro-inflammatory
cytokines and continued tissue degradation [21]. Plasma cells are now the dominant immune
cells. Continued T-cell response leads to the release of interleukins, TNF-α and prostaglandin
E2, being mainly responsible for the alveolar bone destruction [22].

4

Clinical Significance. The high prevalence of periodontal disease in developing and
industrialized countries has made it a significant public health concern [14, 23]. The economic
burden of the disease and subsequent treatment can be overwhelming. Oral related issues are the
fourth most expensive disease, contributing up to 5-10% of health-care related costs [23, 24].
There are also corresponding psychological effects as the deterioration of the gum line and tooth
loss can lead to embarrassment and low self-esteem [25, 26]. In addition, poor oral hygiene has
been associated with systemic comorbidities. Brushing and invasive dental procedures allow
bacteria to enter the bloodstream and disseminate to other sites, such as the brain, lungs and
liver, linking periodontal disease to pregnancy complications, respiratory, cardiovascular and
cerebrovascular diseases [23, 27, 28].
Epidemiology. Periodontal diseases are some of the most common bacterial infections
worldwide. It is estimated that approximately 82% of US children and 50% of adults display
overt signs of gingivitis with gingival inflammation and bleeding. This percentage is higher for
both children and adults in developing countries [29]. For the more severe form, it is estimated
that around 46% or 64.7 million US adults 30 years and older have some stage of periodontitis.
Unfortunately, this only increases with age. Chronic periodontitis is most prevalent in adults or
seniors 65 years and older, with approximately 70.1% of the population afflicted [30].
Epidemiological studies have shown clear disparities in the estimated populations affected by
periodontal disease. There are higher incidences of periodontitis in men than women (56.4% vs
38.4%) and higher frequencies in individuals of African (59.1%) and Hispanic descent (63.5%)
[30]. There is also a socioeconomic trend, with individuals with lower socioeconomic status
more likely to present with periodontitis than those with a higher socioeconomic status [29, 31].
Specifically, approximately 65.4% of individuals in the US living below the federal poverty line
5

and 66.9% of individuals with less than a high school education have reported cases of
periodontitis associated tooth loss.
Risk Factors. A risk factor is defined as a variable that has been associated with
increased risk of disease or infection [32] and studies show certain elements contribute to the
development of periodontitis. Smoking, diabetes mellitus, age and stress are all strongly linked to
the development of the disease [32, 33]. While these factors may not directly contribute to the
disease, it is likely that the systemic changes (chronic inflammation and altered immune
response) associated with these factors disrupt the oral ecosystem and contribute to the onset and
prevalence of the disease. For example, patients with diabetes exhibit increased vascular
permeability and impaired neutrophil migration contributing to their increased susceptibility for
the disease [34]. However, it is important to note inherent non-modifiable factors such as genetic
susceptibility and host response play a role in the progression of periodontal disease, as some
people may exhibit one or more of the associated risk factors and never develop the disease [32].
It is widely accepted that the microbial population is a significant risk factor. Initially, it
was believed periodontal disease was a result of the overwhelming presence of total bacteria in
what was known as the non-specific plaque hypothesis [35-37]. However, in the 1970s, the
specific plaque hypothesis was offered, stating that certain species played an etiological role in
the onset. Evidence for this theory began with cariogenic bacteria. Loesche et al. noticed that
antimicrobial therapy with kanamycin targeting oral streptococci reduced caries formation [35,
38, 39]. Following this, Socranksy et al. offered supporting evidence by studying the complex
poly-microbial environment based on the bacterial relationships corresponding to health and
disease state. Socransky recognized that late colonizers Porphyromonas gingivalis, Treponema
denticola and Tannerella forsythia (formerly Bacteroides forsythus) were isolated together from
6

diseased sites and expressed numerous virulence factors, corresponding to the effects of
periodontitis. This bacteria group makes up what is still known as the ‘red complex’ [40, 41].

II.

Porphyromonas gingivalis

One of the main pathogens within the oral cavity is Porphyromonas gingivalis. P. gingivalis is a
Gram-negative non-motile, rod-shaped organism that belongs to the phylum Bacteroidetes and
has long been considered a major causative agent in the onset and progression of periodontal
disease [42, 43]. Identifying characteristics of the bacterium include anaerobic respiration, which
is the degradation of amino acids for energy and the accumulation of hemin on the cell surface
for the acquisition of iron, forming the characteristic black colonies on blood agar. P. gingivalis
has been isolated from the oral cavity [18], the respiratory tract [44, 45], and from the vagina of
women with bacterial vaginosis [46]. The genome of virulent P. gingivalis strain W83 was
sequenced in 2003 by Nelson et al. revealing a 2.3 Mbp genome with 2,015 protein-coding genes
[43]. P. gingivalis is a secondary colonizer thriving in nutrient rich areas with reduced oxygen
levels, attaching to streptococci early colonizers [18, 47] as well as other late colonizers such as
Fusobacterium nucleatum and Treponeam denticola [43, 48]. The bacterium is a part of the “red
complex” as it is readily isolated from diseased sites and commonly found with other known oral
pathogens [40, 49]. There is a positive correlation between an increase in periodontal pocket
depth and P. gingivalis colonization [50]. Additionally, studies show there is improvement in
periodontal health following the reduction of P. gingivalis [51]. Colonization and virulence of P.
gingivalis is aided by the expression of protein adhesins, proteinases and hemagglutinins [18].
Virulence factors. A virulence factor is defined as a molecule produced by a pathogenic
organism that contributes to the destructive nature of a disease and enables the pathogen to
7

survive within a specific host [52]. As previously mentioned, numerous studies have revealed a
plethora of virulence factors that contribute to the colonization of P. gingivalis, the subversion of
the host immune response and the destruction of the periodontal structures [18, 52].
Gingipains. P. gingivalis possesses several proteases; however, the most studied belongs to a
group of cell associated and secreted cysteine proteases known as gingipains. Gingipains
contribute to a variety of virulent functions and have been classified based on their enzymatic
specificity: arginine specific gingipains, Rgp and lysine specific gingipains, Kgp [18, 52]. One
major purpose of gingipains is nutrient acquisition. Expression of Rgp and Kgp can induce
epithelial cell death and tissue degradation that results in attainable nutrients for the bacteria
within the environment [53]. It is also thought that P. gingivalis utilizes gingipains to break
down transferrin and hemoglobin to obtain the iron necessary for survival [54]. This theory was
supported by studying ginipain-deficient P. gingivalis cells. These mutants lost their
characteristic black pigment on blood agar and their ability to bind hemoglobin [55, 56].
Gingipains also play a role in the deregulation of the host immune defense. Studies show that
gingipains possess complement-like convertase activity by cleaving complement components
and allowing for immune dysregulation [57, 58].
Fimbriae. The fimbriae are long protein structures peritrichously arranged on the outer cell
surface of the bacteria and facilitate adhesion to the surfaces of the oral cavity as well as other
bacteria. Addition of purified monoclonal anti-fimbriae antibodies prevented binding and
colonization of P. gingivalis to oral epithelial cells [59, 60] and strains of P. gingivalis with short
or very few fimbriae were typically non-adherent to host cells [52]. The fimbriae may also play a
role in periodontitis associated tissue destruction as immunization against P. gingivalis fimbriae
in a rat model prevented tissue breakdown and characteristic periodontal destruction [52, 61].
8

Hemagglutinins. Hemagglutinins are microbial lectins or adhesins expressed on the bacterial
cell surface and are essential for the initial attachment and establishment of infection. Binding is
mediated through glycan receptors on host cells which may be facilitated by the fimbriae.
Consequently, studies show antibodies against hemagglutinin HagB in P. gingivalis significantly
reduced attachment to endothelial cells [62]. Hemagglutinins have long been associated with
virulence as they may agglutinate erythrocytes [63] and sequence data shows that certain
hemagglutinins can be co-expressed with genes containing proteolytic activity for the acquisition
of iron [17]. The ability to block attachment and therefore colonization have led to new studies
into vaccines targeting hemagglutinins as potential therapeutics [63].
Lipopolysaccharide. Lipopolysaccharide (LPS) is a glycolipid found on the outer membrane
of the bacterial cell surface. It is a potent immunostimulant, generating an array of
immunological responses triggering inflammation and tissue destruction. P. gingivalis LPS has
been shown to be endotoxic since the bacteria has the ability to release LPS in vesicles [64],
which can then enter the host tissues [65, 66]. The interaction of LPS with the host tissues
induces hallmark pro-inflammatory cytokines such as IL-1β, TNF-α and IL-6. Recognition of
LPS can directly stimulate osteoclasts leading to the release of IL-1β and TNF-α from various
immune cells causing the hallmark signs of periodontitis: bone resorption and tissue destruction
[17]. Toll-like receptor 4 (TLR4) is the major signal transducer for bacterial lipopolysaccharides;
however, the P. gingivalis lipid A moiety of LPS has been described as atypical. It is less potent
compared to other bacterial LPS. Furthermore, it is agonistic against TLR2, while being both
antagonistic and agonistic for TLR4 [67]. This may be due to the differences in the chemical
composition in response to environmental cues (i.e., fatty acid chain heterogeneity [68], changes
in acylation patterns or phosphorylation of the lipid A moiety [17, 67]). The ability to alter the
9

LPS structure can be beneficial to P. gingivalis survival through manipulation of the innate
immune response. This response suppresses inflammation and immune clearance early during
infection, then later induces inflammation for nutrient acquisition. Furthermore, studies show
that the atypical P. gingivalis LPS is able to down-regulate the stimulatory effect of other
bacterial LPS by TLR4, which may stimulate E-selection on endothelial cells, thereby preventing
neutrophil migration and evading clearance [17, 69].

Keystone pathogen hypothesis. The ecological application of the term “keystone” refers to a
species that is present in low numbers relative to the total population but still plays a major role
in maintaining the integrity of the community [70]. Historically, P. gingivalis is known to be
highly associated with the clinical signs of periodontal disease such as oral lesions and bone loss,
while accounting for a small fraction of the oral population [71]. Evidence suggesting P.
gingivalis could be a “keystone pathogen” began from a study when P. gingivalis colonized at
less than 0.01% in specific-pathogen free mice, induced destructive periodontitis. These effects
were not observed in germ-free mice, indicating the onset of periodontal disease is related to
changes in the microbial population induced by P. gingivalis [58]. This was further characterized
by showing that the colonization of P. gingivalis selectively modified the host immune response
leading to the disruption of the normal host microbiota [58]. Following colonization, P.
gingivalis prevented epithelial cell secretion of IL-8, a chemoattractant for PMN that hindered
neutrophil migration and attenuated the first line of immune defense [58, 72, 73]. Interestingly,
this colonization also prevented complement activation, which facilitated in the survival of the
periodontal pathogen, the increase in commensal bacterial load and induction of bone loss [58].
P. gingivalis cleaves the complement component C5 into C5a by gingipains [74] and the
downstream effect of C5aR in conjunction with TLR2 stimulated by the pathogen-associated
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LPS leads to a break within the signaling pathway preventing phagocytosis. This interaction is
important to the dysregulation as gingipain-deficient strains of P. gingivalis show no changes in
the oral micro-environment maintaining the bacterial balance [75, 76]. The interaction with
TLR2 prevents the production of IL-12 cytokines, but increases proinflammatory mediators IL1β, IL-6 and TNF-α. This selective immunosuppressive mechanism aids P. gingivalis in resisting
immune clearance while allowing for cytokines that are involved in bone resorption and tissue
degradation to generate a nutrient rich, inflamed site [77]. The now altered oral environment may
select for asaccharolytic organisms such as P. gingivalis since they are able to utilize available
nutrients. In addition, the degeneration of alveolar bone provides new niches for pathogenic
species. P. gingivalis also alters macrophage function. The bacteria interact with lipid rafts on
the macrophage cell surface, allowing for a close interaction between FimA and CXCR4 and
TLR2 on the macrophage cell surface. Crosstalk between the two receptors increases cAMP
levels and inhibits the oxidative burst facilitated clearance by macrophages [45, 78].
P. gingivalis as a potential target. Corresponding to the evidence of being a keystone pathogen,
studies of immunization directed specifically against P. gingivalis have shown promise as a
therapeutic strategy for periodontal disease. Mice immunized with purified P. gingivalis capsular
polysaccharide developed high IgM and IgG serum titers, which elicited protection against P.
gingivalis-induced bone loss [79]. Several studies have shown success in targeting outermembrane proteins (OMP) [80-83]. For instance, P. gingivalis-challenged mice exhibited
decreased oral lesions when immunized against recombinant forms of an OMP-like protein [83].
Another study using a rat model examining immunization against the adhesin motif of
hemagglutinin HagB showed a reduction in periodontitis associated bone loss [62, 84, 85]. A
study in non-human primates, vaccinating against an outer membrane protein or a lysine
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gingipain protease complex significantly reduced alveolar bone loss and decreased P. gingivalis
cell viability [86, 87]. Finally, a human clinical study providing repeated applications of
monoclonal antibodies specific to a P. gingivalis protease complex prevented recolonization of
the pathogen for approximately 9 months, leading to significant improvement of oral health [84,
88].

III.

Antibiotics

Antibiotics or antimicrobials are some of the most commonly prescribed medications worldwide
[89] and describe any molecule that targets essential functions (e.g., DNA replication, protein
synthesis, cell wall synthesis and cell membrane) to kill or stop the growth of infectious
organisms [90-92]. Around 1930, the modern “golden age” of antimicrobial research began,
representing one of the greatest medical achievements [93, 94]. Beginning in the early 1900s,
Paul Ehrlich hypothesized the possibility of selectively targeting pathogenic microbes while
sparing the host [90]. However, it wasn’t until 1928 that the theory became a reality when
Alexander Flemming made a fortuitous discovery that resulted in the wide spread use of
penicillin [90]. Spanning a 40-year period, researchers and pharmaceutical companies examined
microbial and fungal metabolites for naturally occurring antibiotics leading to discovery of the
major antibiotic class scaffolds: cephalosporins, penicillins, quinolones and macrolides, still used
today [90, 95]. During this period, steady progress was made with improvements in the form of
second and third generation synthetic derivatives, resulting in various β-lactams, sulfonamides,
and aminoglycosides then tetracyclines, macrolides and glycopeptides [90, 95, 96]. By the
1980s, development began to slow. The ideal natural sources had been exhausted, leading to a
drop in progress and interest. Any newly designed antimicrobials, by that point, were chemical
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modifications of common core scaffolds and targets, incrementally improving potency and
efficacy. A few novel compounds were identified however, but none made it to market until
years later. This included linezolid, an oxazolidinone class discovered in 1978, approved in
2000, daptomycin, a lipopeptide antibiotic discovered in 1986, approved in 2003 and
retapamulin, a pleuromutilin approved in 2007 [93].
Antibiotic resistance. The discovery of antimicrobials brought about a significant turn in the
constant battle against bacterial infections, increasing both the quality and span of the average
life [92, 97]. However, the rise of antibiotic resistance has threatened to diminish this feat,
rendering many antibiotics ineffective. Resistance is defined as a change in the bacteria’s level of
susceptibility to a drug, in regards to the normal population. This change can occur through
mutations or the acquirement of heterologous genes coding for resistance by means of horizontal
gene transfer [98]. Once expressed, the acquired gene provides a selective advantage for the
pathogen when exposed to antibiotics leading to the spread and dominance of resistant strains
within the population [90]. Mechanistically, bacterial resistance can occur in four ways. First, the
modification of the drug target. For example, resistance to the glycopeptide vancomycin is
mediated through the acquired vanA gene. VanA codes for an enzyme that synthesizes a
peptidoglycan with one less hydrogen bond, decreasing vancomycin’s affinity by 1000-fold.
Second is the inactivation of the drug. Aminoglycoside antibiotics such as kanamycin are left
ineffective due to the production of aminoglycoside-modifying enzymes that covalently attach a
moiety (e.g., phosphate, acetyl or adenyl) to a key functional group of the antibiotic. This
modification is a steric hinderance to binding of the ribosome. The third method is
impermeability, such as the down-regulation of porins. Fourth, resistance can occur through the
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explusion of the drug. Streptogramin resistance by E. faecalis is partially due to the presence of
ABC transporter Lsa, which removes the drug and prevents access to the target [98-101].
Antibiotic resistance not only increases healthcare related cost forcing the use of more
expensive drugs and prolonging treatment times, but it is a significant threat to our morbidity and
mortality [98]. By 2004, it was documented that approximately 70% of pathogenic bacteria were
resistant to at least one antibiotic. This has resulted in at least two million illnesses and 23,000
deaths, adding an additional $20 billion to healthcare cost [102]. Rising resistance in
Staphylococcus aureus is one well-known example. This Gram-positive pathogen
asymptomatically colonizes 30% of the population and is known to be extremely adaptable
against antibiotic pressure [103, 104]. By the beginning of 1950, shortly following the
introduction of penicillin into clinical practice, a large proportion of hospital staphylococcal
infections were already penicillin-resistant [105]. Initially only found throughout hospitals,
within a few years, penicillin-resistant strains began causing community acquired infections.
This led to the use of methicillin as the first drug of choice. Nevertheless, by 1961, cases of
methicillin-resistant Staphylococcus aureus (MRSA) were on the rise in the United Kingdom and
by the 1980s, MRSA infections were widespread within the United States [104, 106, 107]. From
that point, vancomycin became the last line of effective antibiotics. Again, antibiotic pressure led
to the emergence of vancomycin-intermediate S. aureus strains (VISA) and by 2002, cases of
strains displaying complete resistance or vancomycin-resistant S. aureus strains (VRSA) were
found within the US [104]. In 2006 the CDC reported antibiotic resistant S. aureus infections
such as pneumonia, sepsis and necrotizing fasciitis, resulted in approximately 19,000 deaths [95,
102]. Re-emerging pathogens such as Mycobacterium tuberculosis, the etiological agent for
tuberculosis (TB), add another layer of concern. While TB infections were once on the decline,
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in 2013 there were around 480,000 new multi-drug resistant TB (MDR-TB) cases and 100
countries reporting cases of extensively-drug resistant TB (XDR-TB) strains resistant to first-line
and second-line therapies [92, 108, 109]. XDR-TB is extremely difficult to treat, requiring at
least two years of antimicrobial therapy. Additionally, effective therapy typically relies on
antibiotic drugs that are expensive, toxic and potentially lethal [95].
Antibiotics and the microbiome. Humans are colonized with over 100 trillion bacteria, which
led to a symbiotic host-microbe relationship [110]. The microbiome plays important functional
roles, from establishing our immune system after birth [111, 112] to influencing how our brains
process information [113, 114]. Since the Human Microbiome Project, there has been growing
interest in the healthy human microbiome and how changes in it relate to the development of
disease [3, 110, 115, 116]. Therefore, it is not surprising that disruption in that normal microbiota
(as a result of the overuse or misuse of broad-spectrum antibiotics) has been linked to a multitude
of systemic diseases. Reoccurring Clostridium difficile infection is a distinctive case of changes
in the microbiome due to antibiotic therapy. Usage of antimicrobials disrupts the normal gut
microbiota allowing for the colonization of C. difficile, resulting in fever, severe diarrhea and
colitis [117]. Research has begun linking the alteration of the microbiome to obesity. Ley et al.
noted significant changes in the dominant gastrointestinal microbial species in obese mice
compared to lean mice [118]. Correspondingly, mice given the fecal extract from an obese twin
subsequently led to weight gain, while the extract from the leaner twin did not [119]. Infants
treated with ampicillin/gentamicin soon after birth showed a decrease in beneficial gut species
that did not recover within 8 weeks post treatment and increased the incidence of weight gain
[120, 121].
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This brings in to play the rationale for alternative strategies such as narrow-spectrum or
pathogenic-specific antimicrobials. Improvements in diagnostics have decreased the time it takes
to identify the etiological agent and narrow-spectrum treatment can be more cost effective longterm. Antibiotics drug design against a limited population may also lead to faster discovery rates
as targets will not need to be conserved or effective across a range of disparate species. With
rising resistance, the necessity of maintaining the healthy microbial population and progress in
general antimicrobial development of novel approaches are imperative.
Strategies in antimicrobial drug discovery. Drug discovery is a multi-step process spanning
from target selection to drug optimization and clinical trials [122]. Historically, there have been
two main approaches to antimicrobial drug discovery: empirical screening and target-based
discovery (Fig 1). The empirical approach involved whole-cell based, trial and error screening of
naturally occurring compounds or their synthetic derivatives. Compounds displaying growth
inhibition against the desired spectrum of bacteria would be screened for eukaryotic cytotoxicity,
followed by secondary screening to identify the mode of action. Biological assays would be used
to verify the activity of the compound, ending with optimization and development for clinical
trials [97]. By the early 1990s it was clear, even though successful in the past, this could no
longer provide the results needed. The decreasing success of this process was due to the fact it
was: (1) expensive and time consuming, while yielding a poor return for the effort [94, 123]; (2)
had been depleted of easily obtainable products isolated from organisms culturable at the time
[97]; and (3) changes in regulatory policies made it increasingly difficult to obtain clinical
approval [124].
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Figure 1. Workflow for two methods of antimicrobial drug discovery.
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In 1995, the DNA sequence for the genome of Haemophilus influenza was completed
[125], promising new approaches for the challenges in drug discovery and renewed excitement
by various pharmaceutical companies such as GlaxoSmithKline (GSK), Merck, Pfizer, and
Wyeth [126]. Before then, few genome maps were publicly available, leaving researchers with
the ability to only examine small areas of a specific sequence. With increased computational
power and the availability of whole genomes, bioinformatics analysis allowed for the
examination of new gene targets from various species [127]. Screening strategies then shifted to
target-based drug design. The initial strategy was to focus on identifying as many potential
targets available within a genome and one could then work to inhibit the targets by a highthroughput screening (HTS) of drug-like compounds instead of blindly searching for compounds
with antibacterial activity [97]. One prime example of the boom in research during the genomic
age was that of GlaxoSmithKline (GSK). From 1995-2002, GSK attempted to identify a
compound with Gram-positive or broad-spectrum antimicrobial activity. Using Streptococcus
pneumoniae as the primary comparison genome, GSK analyzed genes across five pathogens for
highly-conserved sequences resulting in more than 350 S. pneumoniae, S. aureus, and H.
influenzae candidate target genes. From the 350 potential genes, 127 were classified as essential
in vitro in at least one of the three organisms and 64 targets displayed attenuated growth in vivo.
The company screened targets against more than 250,000 compounds from their library [126].
The screening led to 16 positive ‘hits’, five which went on to ‘lead’ compounds. Of the five
targets (FabH, FabI, peptide deformylase, methionine tRNA synthetase, and phenylalanine tRNA
synthetase) only one, peptide deformylase, led to an optimized lead molecule (GSK 1322322)
that successfully went on to Phase II clinical trials [124, 126, 128]. The disappointing results
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produced during these large screens were partially due to the newness of the era, the lack of
knowledge of suitable targets and the feasibility of the HTS [97, 126].
Current strategies shifted towards a rational structure-based approach due to technological
advances in genomic sequencing, high resolution protein structures and computational modeling.
This led to a better understanding of the bacteria and target proteins [97, 129-131]. The basic
concept is that the structural properties of a specific target relates to its biological activity and
modification of the target will have therapeutic effects. Computer-aided molecular modeling of
protein structures allows for virtual HTS screening of compounds rationally determined to interact
with the target [131]. As a result, the initial trial-and-error of drug discovery is reduced as inhibitors
are selected based on structural properties and there are increases in the screening efficiency since
compounds have a higher chance of binding [129]. This approach was successful in the relatively
rapid design of Iclaprim, a structural derivative of trimethoprim. Trimethoprim resistance in S.
aureus is a result of a single amino acid substitution of the target dihydrofolate reductase (DHFR),
resulting in a 20-fold decrease in affinity due to the loss of a hydrogen bond. Through molecular
modeling of the mutated DHFR, Iclaprim was designed with a trimethochromene side chain in
place of the original trimethophenyl resulting in a 20-fold increase in binding affinity, maintaining
potency [97, 132].

IV.

Summary

Currently, supplemental therapy for destructive periodontal disease can include the application of
broad-spectrum antibiotics [133-135]. However, we now know that this is not ideal as it can alter
the essential microbiome and runs the risk of promoting antibiotic resistance. While the oral
cavity is a complex poly-microbial environment, it is evident that the interaction of specific

20

species disrupts the oral homeostasis, triggering the onset of periodontal disease. The hypothesis
of P. gingivalis being a key player in the initiation of periodontitis suggests the potential for
novel narrow-spectrum therapeutics. By targeting the key pathogens, it may be possible to treat
periodontitis while allowing for the recolonization of the beneficial, healthy flora. In this study,
we present a unique approach to predict essential gene targets selective for the periodontal
pathogen within the oral environment. We then utilize a rational-based approach to identify
small-molecule inhibitors for the potential development of antimicrobial agents against P.
gingivalis and periodontal disease. We believe by using P. gingivalis and periodontal disease as a
model we can begin to develop an approach for pathogen-specific antimicrobial drug discovery.

V.

Outline

Following the general introduction and summary, the main goals of this dissertation are divided
into three chapters. Background, methodologies, results and discussion relating to the specific
aim are reported for each chapter.
Chapter One focuses on the development and verification of the framework for a novel essential
gene prediction model. The benefit of the model is displayed through the quick and accurate
selection of a potential species-selective drug target in the Gram-negative periodontal pathogen,
P. gingivalis.
Chapter Two continues the evaluation of the potential drug target identified in Chapter One.
The application of a CBDD method is used to identify new target specific inhibitors.
Chapter Three details the biochemical screening from the compounds identified in Chapter
Two. A target-based and whole-cell based approach is used to assess in vitro activity.
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This is concluded with an overall summary and conclusion.
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Chapter One
Applying a Novel Framework for the Prediction of Essential Genes as
Antimicrobial Targets

Victoria N. Stone, Brian A. Klein, Linden Hu and Ping Xu

Victoria N. Stone performed the prediction, the analysis of data and the preparation of the
following manuscript. Dr. Brian A. Klein performed the mutagenesis experiments and aided in
analysis of data. Dr. Ping Xu and Dr. Linden Hu acted as advisors.

23

Background
With the onset of the genomics era came the availability of completed genome sequences and put
new focus on the study of essential genes that held the promise of a wealth of biological and
genomic data. Identification of these genes enhances our knowledge of gene regulatory networks
[136] and aids in our understanding of cellular functions [137]. They can provide clues to the
origins of life through the examination of the minimal genome [138] and evolutionary
divergence [136, 137, 139]. Additionally, the understanding of the minimal number of genes
required to sustain life supports research for the developing field of synthetic biology [138, 140].
Essential genes, by definition, are critical for the growth and/or survival of an organism.
Antimicrobials target key metabolic and cellular functions, making essential genes attractive
targets for drug discovery. Hu et al. was able to successfully identify drug targets for the fungus
Aspergillus fumigatus from in vivo mouse model essential gene studies [141]. This has become
more important with increasing rates of antibiotic resistance. Furthermore, the discovery of
genome-wide essential gene data can present previously unexplored therapeutic targets [99, 142].
To date, a variety of approaches have been utilized to identify essential genes in a number
of organisms. Large-scale experimental approaches such as systematic single gene deletions
[139, 143-147], random transposon mutagenesis [148-151] and RNA interference [152, 153]
utilize gene disruptions to evaluate the viability of the organism. However, these approaches can
be extremely time-consuming, expensive and technically difficult with certain microbial systems.
Due to the large investment, comprehensive experimental essential gene data is not readily
available for the majority of sequenced genomes [154]. Currently only 31 species have genomewide experimental data that has been deposited into the Database of Essential Genes (DEG)
[155]. Computational assessment of bacterial systems offer alternatives to experimental
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procedures. In silico methods rely on information garnered from experimentally identified
essential genes to predict essentiality based on orthologous genes, protein expression,
phylogenetic conservation, similar GC content and codon usage [136]. These bioinformatics
approaches have recently become standard for the prediction of essential genes. Unfortunately,
orthologous genes account for only a fraction of the total genome and as genetic diversity
increases in phylogenetically unrelated organisms, prediction accuracy decreases due to variation
in gene sequences, alternate cellular pathways and genetic redundancy [136, 156]. In addition,
experimental essential gene data, which in silico approaches are based on, is only available in a
fraction of species and differences in experimental parameters (bacteria grown in rich versus
minimal medium), mutagenesis techniques (site-directed versus random transposon insertion) or
simply the definition of essential has led to a lack of consensus, making predictions difficult
[140, 142].
Previously, we conducted a genome-wide essential gene identification study in the Grampositive, early oral colonizer Streptococcus sanguinis using systematic single and double gene
deletions [139]. These essential genes were grouped by specific categories based on their KEGG
functional annotation. Once linked together, we were able to create a model of essential
pathways and determined that essential genes were conserved within three major categories of
biological function: maintenance of the cell envelope, energy production and processing of
genetic information. These three features also follow the ideal for what is considered the core of
the hypothetical minimal genome encompassing the basic components necessary for cell survival
[138, 140, 157]. Studies show that although essential genes themselves may diverge or change,
the essential function remains relatively unaltered [140]. From these observations we established
a framework to predict essential genes based on genome annotation and function. Our prediction
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does not rely on sequence features among different species, but a gene’s contribution to an
essential end product or the overall essential function that it plays. We believe that the reliance
on genomic function instead of sequence addresses inconsistencies of essential gene data among
different bacterial species as a result of genetic diversity while still allowing for an accurate
prediction [140]. Furthermore, as a predictive method our approach simply requires a sequenced
and annotated genome, bypassing the need for previous experimental data from closely related
species. When lacking comprehensive essential gene datasets, we believe our approach provides
a quick and accurate prediction of essential genes within the genome of different organisms. This
could be extremely beneficial, especially when concerning drug target identification of emerging
pathogens or difficult to culture organisms. Knowledge based on metabolic or gene functional
networks have increasingly become an invaluable tool [158]. This was evident when a previous
genome-scale study with metabolic networks, similarly based on genome information, showed
high accuracy in the prediction of amino acid preference and by-product secretion rates [159].
In this study, we demonstrate the framework for our essential gene predictive model is
both accurate and useful for the identification of antimicrobial targets. First, using KEGG
pathways and genome annotation, we identify relevant pathways and predict essential genes for
the periodontal pathogen Porphyromonas gingivalis. The selection of P. gingivalis to evaluate
our accuracy was valuable as it is phylogenetically distinct from S. sanguinis, from which the
prediction model was derived. Second, we cross-validate our prediction with experimental data.
During our study, P. gingivalis lacked a large-scale essential gene study. However, a genomewide Mariner-based transposon mutagenesis study was recently carried out [Klein BA,
unpublished], allowing us to verify the accuracy of our prediction. Third, we identify P.
gingivalis-selective essential gene targets, through the comparison of essential gene data sets
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between the primary, non-pathogenic colonizer, S. sanguinis [139] and P. gingivalis. Last, based
on “druggable” target criteria, we select a promising candidate target to experimentally
characterize for future drug development studies.

Materials and Methods
Bacterial Strains, plasmids and growth conditions. Porphyromonas gingivalis W83 strain was
cultured anaerobically (10% CO2, 10% H2, and 80% N2) at 37 °C in tryptic soy broth (TSB)
(Becton Dickinson, Franklin Lakes, NJ) supplemented with 1 µg/ml menadione and 5 µg/ml
hemin. When appropriate, erythromycin (Fisher Scientific, Fair Lawn, NJ) was used at a
concentration of 5 µg/ml. Plasmid pVA2198 (Richmond, VA) [160] was used to isolate the
erythromycin resistance cassette.
Prediction of P. gingivalis essential genes. The prediction of essential genes was based on data
derived from Xu et al. [139]. Using the Kyoto Encyclopedia of Genes and Genomes (KEGG)
database [161] for the genome-wide analysis of P. gingivalis strain W83, pathways such as
glycolysis and fatty acid biosynthesis that were related to the three broader categories previously
described (maintenance of the cell envelope, energy production and processing of genetic
information) were manually examined and a network of predicted essential pathways was
determined. We identified genes whose function singularly contributed to the formation of an
essential end product for each of the pathways within our described network. Alternative
pathways would be noted for any essential pathways within our network and paralogs/isozymes
of predicted essential genes would be noted and listed as putatively essential. The assigned KO
numbers and path numbers of genes predicted to be essential were listed and grouped by
biological function. Multiple KO numbers or path numbers from KEGG were often assigned for
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a single gene if it was involved in different pathways. Predicted essential gene functions wrongly
annotated or missing annotation would be predicted by BLAST comparison of genes with similar
gene functions from phylogenetically similar species.
Gene functions assignment. To determine putative gene function, protein sequences were
searched against annotated Porphyromonas gingivalis strain W83. The Cluster of Orthologous
Groups (COG) annotation [162] was downloaded from the NCBI database and essential
pathways were analyzed via the KEGG database [161]. Putative gene functions and COGs were
recorded for predicted essential genes and the total number of genes in the genome. Ratios of the
number of essential genes for each COG and the total number of genes belonging to a specific
COG category were calculated.
Comparison of Essential Gene Homologs. To identify essential genes conserved in P.
gingivalis W83, a comparative genomics analysis was performed. Thirty-one other organisms
with essential genes annotated in the DEG v10.0 [163] were obtained and protein sequence
conservation was determined by BLASTP. Significant matches (E <1e-5) were analyzed to find
homologs to P. gingivalis genes. Protein sequence conservation was calculated by percent amino
acid identity.
Multiple sequence alignment. For the prediction of the substrate binding site, the protein
knowledge database, UniProtKB/Swiss-Prot (www.uniprot.org) [164], was referenced for
organisms with completed enzymatic and functional data for m-Ddh. This included
Corynebacterium glutamicum ATCC 27405, Lysinibacillus sphaericus, Bacteroides fragilis
ATCC 25285, Clostridium thermocellum ATCC 13032 and Ureibacillus thermosphaericus
(Uniprot ID: P04964, Q9KWR0, Q5L9Q6, A3DDX7, G1UII1). Complete protein sequences
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were obtained from the National Center for Biotechnology Information (NCBI,
www.ncbi.nlm.nih.gov/) database. Sequence alignment analyses were then performed using the
ClustalW multiple alignment [165] via the BioEdit program v7.1.7. The alignment figure was
generated in Espript 3.0 [166] for visualization.
Primer design and recombinant PCR product construction. Primer design was based on the
method of Xu et al. [139]. Two sets of primers, F1/F2 (5’- CTC CGA ATA GCA AAC ATC
TAC TG -3’ and 5’- GAA AAA TTT CAT CCT TCG TAG TCG AGC AGC CAT GCG C -3’)
and F3/R3 (5’- GGG CAA TTT CTT TTT TGT CAT TTG TCA AAT CTG GGG G -3’ and 5’GAT AAT CAT GCT TCG GAG ATG -3’), were designed to amplify a 1.2kb sequence
upstream and downstream, respectively, of the P. gingivalis target gene. A third primer set,
F2/R2 (5’- GCG CAT GGC TGC TCG ACT ACG AAG GAT GAA ATT TTT C -3’ and 5’CCC CCA GAT TTG ACA AAT GAC AAA AAA GAA ATT GCC C -3’) was designed to
amplify the 800 bp erythromycin resistance cassette (ErmR) containing the ermF gene from
plasmid pVA2198. To minimize polar effects from mutagenesis, primers were designed to
include stop codons within frame and the antibiotic resistance cassette was designed to run in the
same orientation as the target gene to ensure transcription. The three PCR fragments were
created using F1/R1, F2/R2 and F3/R3. All PCR reactions were performed with an initial
denature of 98 ˚C for 30 sec, 30 cycles of 98 ˚C for 10 sec, 56 ˚C for 30 sec, 72 ˚C for 36 sec and
a final extension of 72 ˚C for 7 min. The PCR products were purified using QIAquick PCR
Purification Kit (Qiagen, Valencia, CA); the three fragments were then combined in equal
amounts and amplified again using F1 and R3 primers to generate the final linear recombinant
product. The PCR reaction was performed with an initial denature of 98 ˚C for 30 sec, 30 cycles
of 98 ˚C for 10 sec, 56 ˚C for 30 sec, 72 ˚C for 1 min 36 sec and a final extension of 72 ˚C for 7
29

min. Phusion High-Fidelity Taq DNA polymerase (New England Biolabs, Ipswich, MA) was
used in all reactions.
Transformation. The electroporation method was adapted from Fletcher et al. [167]. Briefly,
0.2 ml of an actively growing culture of P. gingivalis was used to inoculate 2 ml of TSB
supplemented with yeast extract, hemin and menadione, which was then incubated overnight at
37 ˚C. Five ml of the same medium pre-warmed to 37 ˚C was then inoculated with 0.5 ml of the
overnight culture and was incubated for an additional 4 h (OD600 ≈ 0.7). The cells were harvested
by centrifugation at 6,000 × g for 15 min at 4 ˚C and washed twice in 10 ml of ice-cold
electroporation buffer (10% glycerol, 1 mM MgCl2). The final cell pellet was re-suspended in
0.5 ml of electroporation buffer. A 100 l sample of re-suspended cells and 5 µg of DNA were
placed in a sterile electrode cuvette (0.2-cm gap). The cells were then pulsed with a Bio-Rad
(Hercules, Calif.) gene pulser at 2,500 V for 9.5 ms and incubated on ice for 5 min. The cell
suspension was then added to 0.6 ml of TSB broth supplemented with yeast extract, hemin and
menadione and incubated for approximately 16 h. A 100 l sample was plated on 5% sheep
blood agar medium containing erythromycin and incubated anaerobically at 37 ˚C for 5 to 10
days.

Results
Defining our framework of essential gene prediction. The definition of gene essentiality can
vary between researchers, by experimental parameters and/or growth conditions. Genes that are
essential for growth in minimal medium or during in vivo conditions may not necessarily reflect
what is essential for survival in ‘ideal’ laboratory conditions. Also, a deletion or mutation of a
defined essential gene may not be lethal but may lead to decreased fitness [168]. These
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discrepancies are clear in the model organism Escherichia coli. Studies performed by several
laboratories, showed clear differences in their definition and number of experimentally identified
essential genes. Gerdes et al. performed genome-wide transposon mutagenesis in 2003, where
they identified 609 essential genes [169], the Keio collection is currently defined as 296 essential
genes [143] and a metabolic study described 119 genes as being conditionally essential [170]. In
this study we focused our prediction on genes we considered to be necessary for growth in rich
media, implying that certain vitamins, amino acids and nucleotide precursors would be provided.
These genes represent the ‘core’ of the cell’s biological and cellular functions and would be
considered essential in typical experimental in vitro conditions [171]. Furthermore, as these core
essential functions are crucial to bacterial fitness, they represent a set of genes less affected by
evolutionary processes [172-174].
From experimental studies in S. sanguinis SK36 [139], we saw that, while essential genes
were distributed in various pathways, they could be associated through key biochemical
pathways or functions. Genes required for peptidoglycan biosynthesis, terpenoid backbone
biosynthesis, glycerophospholipid metabolism and fatty acid biosynthesis all related to the
maintenance of the cell envelope. The pentose phosphate pathway and glycolysis provided
energy. Nucleotide biosynthesis, DNA replication, cell division proteins, and protein
biosynthesis were associated with the processing of the cell’s genetic information. In order to
predict essential genes, we identified essential metabolic pathways corresponding to the three
core biological functions. The functional genome annotation was obtained from the KEGG
database and assigned to genes within the pathways. Our approach defined essential as a gene
whose functional role individually contributed to the formation of a crucial chemical compound.
Therefore the single deletion or mutation of the gene would result in a non-viable cell.
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Prediction of essential genes by gene annotation in P. gingivalis strain W83. To predict
essential genes in P. gingivalis strain W83, we manually examined our essential biochemical
pathway maps through the KEGG database, a workflow schematic is shown in Fig. 2. Annotated
genes were viewed for each pathway and from 1909 protein coding genes, 212 were predicted to
be essential (Fig. 3, for complete list, see Appendix, Supp. Table 1). During our prediction, we
noted several instances of paralogs or potential isozymes (PG1852/PG0223, exonuclease, DNA
polymerase III subunit epsilon; PG0121/PG1258, DNA binding protein HU; and
PG1940/PG0933, elongation factor G). Many paralogous genes code for proteins that have
redundant functions, which is why a majority of computational models predict them to be nonessential. However, it has also been noted that paralogous genes can have distinct roles through
functional divergence [175]. For example, N. meningitidis possess paralogous genes for
glyceraldehyde-3P dehydrogenase (NMB2159 and NMB0207). However, only NMB2159 was
determined to be essential, as NMB2159 is involved in glycolysis and NMB0207 is involved in
gluconeogenesis [176]. As experimental data would be needed to determine if both or one gene
was essential, we listed paralogs as potentially essential. Hypothetical proteins were left out of
our analysis unless a conserved motif and putative function was noted in the KEGG database.
One such example was PG2046, which was annotated as a hypothetical protein in the KEGG
database. Based on our database searches the gene contained a conserved tRNA
methyltransferase motif and had orthologous matches to other tRNA(Ile)-lysidine synthases.
This indicated that the gene might have a putative essential function in tRNA processing.
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Figure 2. Workflow schematic for the prediction model framework.
(a) A strategy to predict essential genes. (b) Example of an essential pathway from S. sanguinis strain
SK36. Circles represent key intermediates; green boxes represent essential genes; red boxes represent
non-essential genes; white boxes represent genes not present within the genome of S. sanguinis.
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Figure 3. Predicted essential genes and corresponding pathways for P. gingivalis strain W83.
The three biological categories associated with essential genes, previously determined from experimental
studies in S. sanguinis SK36, are indicated by color: dark blue, maintenance of cell envelope; grey,
energy production; light green, processing of genetic information. Predicted essential gene numbers
(PG#) are shown in red, predicted non-essential genes are shown in black. Solid arrows indicate
enzymatic reaction, dashed arrows dashed arrow, multistep pathway; blue dashed arrow, products
involved in cell wall and membrane formation; block arrow, product from one pathway serving as input
to another pathway; oval with bold arrow, transporter; slash, separating paralogs. Ado, adenosine; Cyd,
cytidine; DAG, 1,2-diacylglycerol; DHAP, dihydroxyacetone phosphate; DHF, dihydrofolate; L-G3P, snglycerol 3-phosphate; Guo, guanosine; LPA, lysophosphatidic acid; LTA, lipoteichoic acid; PA,
phosphatidic acid; PS, phosphatidylserine; PE, phosphatidylethanolamine; PGP,
phosphatidylglycerophosphate; PG, phosphatidylglycerol; PPP, pentose phosphate pathway; LPS,
lipopolysaccharide; THF, tetrahydrofolate; Urd, uridine. Genes assumed to be essential based on
prediction, but not annotated in the KEGG database, are represented by red letters (see Table 1). Predicted
essential genes associated with ribosome and aminoacyl-tRNA biosynthesis are not indicated here. For
the complete essential gene prediction see Appendix, Supp. Table 1.
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From our assessment of the core essential pathways, we knew certain genes should be
critical to the formation of certain compounds. However, during our analyses we saw that a small
fraction of genes were missing annotations for certain essential functions in the KEGG database,
noted in Fig. 3 as lowercase letters. For example, in the glycolysis pathway, the gene responsible
for the conversion of pyruvate to acetyl-CoA is not noted. To identify these missing genes, we
compared the genome of P. gingivalis against annotated genes in the NCBI database using a
BLASTP analysis. Proteins with e-values of 1×10-8 or less were then prioritized and missing
genes were identified by their potential function or motif (Table 1, Fig. 3).
There is no direct correlation between the number of essential genes and the total number
of genes in the genome as different experimental approaches or conditions may derive various
outcomes. However, on average, essential genes account for around 10-20% of the genome. S.
sanguinis SK36 with 2270 protein encoding genes has 218 essential genes or 9.6% of the
genome [139], S. pneumoniae D39 with 2,046 ORFs has 244 essential genes or 11.9% [146, 147]
the 4,291 protein encoding genes in E. coli MG1655, 620 were assessed to be essential or 14.4%
[169]. B. subtilis 168 resulted in 271 essential genes from a total ORF of 4,099 genes, accounting
for 6.8% of the genome [145] and P. aeruginosa contains 678 putatively essential genes from
5,500 genes or approximately 12% [177]. Our prediction of 212 essential genes accounted for
11% of the genome, fitting with the expected percentage of essential genes within a microbial
genome. Nonetheless, this prediction may not be comprehensive. Some genes could have been
overlooked due to a lack of biological data annotated in the KEGG database, for instance the
lack of annotation for hypothetical genes.
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Table 1. Non-annotated predicted essential genes in P. gingivalis strain W83.
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Functional analysis and examination of predicted essential genes by biological categories.
To ensure that our essential genes followed our model, we next examined them to determine if
they were associated with the three major biological categories. The predicted essential genes in
P. gingivalis were grouped into a pathway based on the KEGG pathway orthology (KO number)
and the final end product. Of the 212 predicted genes, 46 genes fell into the maintenance of the
cell envelope category. About 32% (7% of total predicted essential genes) of those genes were
directly related to peptidoglycan biosynthesis while about 19% (4% of total) were related to fatty
acid biosynthesis. Sixteen genes were involved in energy production with about 69% (5% of
total) related to glycolysis. The majority of the predicted essential genes (148 genes) were
grouped into the processing of genetic information category. About 9% (6% of total) were
related to nucleotide biosynthesis including both and pyrimidine metabolism and 33% (24% of
total) were related to ribosomal biosynthesis. Two genes were involved in the synthesis of
cofactors: PG0957, a riboflavin biosynthesis protein involved in FMN/FAD biosynthesis, and
PG1896, annotated as S-adenosylmethionine (SAM) synthetase. Both of these genes fit into a
variety of metabolic roles, producing energy which feed into other pathways (Fig. 4a).
To further study the functional characteristics of our predicted essential gene list, Clusters
of Orthologous Groups of proteins (COG) [162] classifications were examined. COGs are
defined through protein sequence comparison of completed genomes and functional categories
such as RNA processing and modification, cell motility and lipid metabolism are grouped. A
high number of genes predicted to be essential, were involved in translation, ribosomal structure
and biogenesis (group J; Fig 4b) following other essential gene and minimal genome studies
[143, 157, 162]. These COG functions belong to the information storage and processing category
which includes critical cellular functions that require multiple proteins such as 30S and 50S
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ribosomal proteins, cell division proteins and translation factors. However, the larger total
proportion of genes belonged to COG functional groups that are related to metabolism (group C,
E, F, G, H, I and Q; Fig 4b). COG assignments are influenced by genome annotation. Our
prediction was mostly lacking hypothetical proteins without a functional annotation; therefore,
only eight genes did not have a clearly defined COG function and are classified by general
function. This included GTP-binding proteins era, obgE, engB and engA, acyl carrier proteins
involved in fatty acid biosynthesis fabG and fabK, an oxidoreductase involved in peptidoglycan
biosynthesis, and the ribonuclease Z elaC. This COG distribution is consistent with genes
necessary for in vitro growth under laboratory conditions. Alteration in the environmental
conditions would lead to changes in genes required for survival. Studies show that cells grown
under chemically defined minimal media or during in vivo conditions were not enriched for
translation, ribosomal structure and biogenesis (group J), but for amino acid
transport/metabolism (group E), nucleotide transport/metabolism (group F) and energy
production/conversion (group C) [178]. This suggests there are different needs for different
environmental conditions.
Cross-validation of prediction with experimental validation of essential genes in P.
gingivalis strain W83. To evaluate our model, we performed a comparison of the predicted
essential with putative experimental essential gene data. A transposon mutant library was
generated in P. gingivalis strain W83 using a pSAM_Bt-based Mariner mutagenesis vector as
previously carried out in Klein et al. for the genome-wide mutagenesis of P. gingivalis strain
ATCC 33277 [149]. Approximately 20,000 colonies were pooled following multiple separate
transpositions. Strain W83 proved difficult to obtain transposon mutants, which may be a result
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Figure 4. Pathway association and COG distribution for predicted essential genes in P. gingivalis
strain W83.
(a) Distribution of predicted essential genes divided by pathway and three conserved biological functions.
(b) The number of predicted essential genes and the percent distribution for the total number of predicted
essential genes were calculated for the individual COG function.
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of known capsule and fimbriae structures, characteristic of this strain. A small degree of
resistance to the selective antibiotic (Erm) was also observed, which may point to survival of a
mutant clone being correlated with the expression level of the Erm cassette. Following Illumina
sequencing of two technical replicates, it was determined that about 12,000 distinct insertion
mutants were present in the strain W83-background mutant pool. Around 12,000 insertions is 5fold coverage of the genome, which is sub-optimal for characterization of gene essentiality.
Based on the limited number of insertions relative to the 36,000 distinct insertions in the ATCC
33277-background, we decided to focus on grouping genes as either containing zero insertions or
greater than two insertions, corresponding to putatively essential and putatively non-essential
respectively (Appendix, Supp. Fig. 1) With this grouping guideline, 759 putatively essential and
680 putatively non-essential genes were noted. It is important to note that the guidelines for
determining putatively essential and non-essential in strain W83 were not as stringent as those in
the previous study for strain ATCC 33277 due to the different library complexities.
From 212 predicted essential genes, 173 matched the experimental data, giving us a
prediction accuracy of 81.6% (Fig 5, Supp. Table 1). Of the predicted essential genes not
experimentally validated, three of these genes (PG0223, DNA polymerase III subunit epsilon;
PG0121, DNA binding protein HU; PG0933, elongation factor G) may have been essential if not
for possible isozymes or paralogs to predicted essential genes that were validated (PG1852,
PG1258, PG1940, respectively). A large subset was annotated as hypothetical and therefore
could not be predicted by our model without an assigned cellular function. A majority of these
genes coded for functions that play multiple, non-specific roles. For example, there were several
ABC transporters, ATP-binding proteins, glycoslytransferase and putative transcriptional
regulators. In addition, many of these genes were not linked or associated with biochemical
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pathways in KEGG. Lacking this information made it difficult to assess the essential role the
gene would play to the overall cell survival. KEGG annotations are not necessarily the most upto-date.
Although we were interested in the prediction of essential genes, to further validate the
accuracy of our model, we compared the predicted essential genes to the experimentally
determined non-essential genes to see if there was any overlap between the two data sets. From
680 observed non-essential genes in strain W83 (Appendix, Supp. Table 1), only 7 genes (or 3%
total) were predicted to be essential by our model (Fig. 5). These few false positives were again
due to the presence of potential isozymes, paralogs or alternative pathways. PG0223 and
PG1852, for example, both encode exonuclease DNA polymerase III subunit epsilon involved in
DNA replication. While PG1852 is putatively essential, PG0223 is not. Mis-predictions may also
come from lack of, or incorrect, annotation. In glycolysis, the conversion of PEP to pyruvate by
the irreversible enzyme pyruvate kinase should be essential for energy production by the cell.
However, the annotation for pyruvate kinase was missing in KEGG for P. gingivalis. A
reversible enzyme with a similar function, pyruvate phosphate kinase, is found in some bacteria
for the conversion of pyruvate to PEP and this enzyme was present and annotated as PG1017.
Due to the lack of annotation for pyruvate kinase, we predicted pyruvate phosphate kinase to
play that essential function. As PG1017 was experimentally shown to be non-essential, it is
likely pyruvate kinase has not been noted within the database or another enzyme must be present.
A small number of genes (32 out of 212) were unaccounted for in both the non-essential and
essential experimental data. As mentioned earlier, due to complexities in the experimental
conditions, some genes could not be accurately assigned to a category and therefore left out of
the analysis.
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Figure 5. Cross-validation of prediction to experimental essential gene data.
(a) The number of essential genes shared between those predicted and the experimentally identified
essential and non-essential gene data. (b) The comparison of the number of essential genes between the
predicted essential genes, experimentally identified essential genes and experimentally determined nonessential genes for strain W83 is shown. The blue circle represents the number of predicted genes
correlated with experimental data, orange the number of predicted essential genes correlated with nonessential from experimental data and gray the number of predicted essential genes not accounted for in
experimental data. Approximately 81% of genes predicted to be essential (173 of 212) matched the
experimental essential data set, and only a small fraction (7 of 212) of genes predicted to be essential
were shown to be non-essential.
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Comparison of P. gingivalis and S. sanguinis essential genes. We next compared the essential
gene data predicted for P. gingivalis strain W83 to the experimental data of S. sanguinis strain
SK36. As the healthy oral cavity is composed of roughly 80% streptococcus species [179], we
theorized that selecting orthologous essential genes in P. gingivalis that were absent or not
essential within S. sanguinis would present us with potential antimicrobial targets selective
within the oral cavity for periodontal pathogens. We identified 68 essential genes that were
selective for P. gingivalis (Table 2). It was clear during our analysis that differences were mostly
a result of alternative pathways or genes apart of complexes that we predicted to be essential to
the overall function. A clear example is in regards to cell wall composition. Gram-negative
bacteria possess an outer membrane composed of lipoposaccharide and lipoproteins with a high
lipid content. Gram-positive bacteria express lipoteichoic acid on the cell membrane and is
composed of a high peptidoglycan content. This gave us a different set of essential genes for cell
envelope maintenance. Another key difference lay in terpenoid biosynthesis. S. sanguinis uses
the mevalonic acid pathway, producing terpenoids via the HMG-CoA reductase pathway.
However, P. gingivalis uses the alternate MEP/DOXP or non-mevalonate pathway.
Identification and assessment of meso-diaminopimelate as a target. To assess the value of
our model in drug discovery, we wanted to examine the list of P. gingivalis-selective essential
genes for future therapeutic targets. Sequences for each gene was first searched against the
human genome to eliminate genes with significant human homology. No genes within our list
had a homologous sequence compared to the human genome. Based on what we know of
bacterial metabolism, the lysine biosynthesis pathway presented an attractive option for
pathogen-selective targeting. Lysine is a required amino acid for bacteria and especially
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Table 2. Predicted P. gingivalis-selective essential genes.
Functional
category

KEGG
KO#

GeneID

Name

K03340

PG0806

-

K01921

PG0729

Ddl

K01929

PG1106

murF

K01000

PG0577

mraY

K02563

PG0580

murG

K05366

PG0794

pbp1a

K03587

PG0575

-

K00215

PG2002

dapB

K00928

PG2189

lysC

K00133

PG0571

asd

K01714

PG2052

dapA

K01662

PG2217

dxs

K00099

PG1364

dxr

K00991

PG1434

ispD

K00919

PG0935

ispE

K01770

PG0028

ispF

K03526

PG0952

ispG

K03527

PG0604

ispH

Terpenoid backbone
biosynthesis

K00806

PG0190

uppS

Polysaccharide
transporter

-

PG0117

-

Lipopolysaccharide
biosynthesis

K00677

PG0070

lpxA

KEGG Pathway

Peptidoglycan
biosynthesis

Cell envelope

Terpenoid backbone
biosynthesis
(MEP/DOXP pathway)
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Protein ID
Gfo/Idh/MocA family
oxidoreductase
D-alanyl-alanine
synthetase A
D-Ala-D-Ala adding
enzyme
phospho-Nacetylmuramoylpentapeptide-transferase
N-acetylglucosaminyl
transferase
penicillin-binding
protein 1A
penicillin-binding
protein 2
dihydrodipicolinate
reductase
aspartate kinase
aspartate-semialdehyde
dehydrogenase
dihydrodipicolinate
synthase
1-deoxy-D-xylulose-5phosphate synthase
1-deoxy-D-xylulose 5phosphate
reductoisomerase
2-C-methyl-D-erythritol
4-phosphate
cytidylyltransferase
4-diphosphocytidyl-2-Cmethyl-D-erythritol
kinase
2-C-methyl-D-erythritol
2,4-cyclodiphosphate
synthase
4-hydroxy-3-methylbut2-en-1-yl diphosphate
synthase
4-hydroxy-3-methylbut2-enyl diphosphate
reductase
undecaprenyl
pyrophosphate
synthetase
polysaccharide transport
protein
UDP-Nacetylglucosamine
acyltransferase

Glycerophospholipid
metabolism/glycerolipi
d metabolism

Glycolysis /
Gluconeogenesis
Energy
production
Pentose phosphate
pathway
Nicotinate and
nicotinamide
metabolism
Pyrimidine metabolism

Genetic
information
processing

K02372

PG0071

lpxC

K02536

PG0072

lpxD

K00912

PG0638

lpxK

K02527

PG1565

-

K02517

PG2222

-

K00057

PG1369

gpsA

K00980

PG2068

tagD

K01835

PG2010

pgm

K04041

PG0793

fbp

K15634

PG1513

-

K01006

PG1017

ppdk

K01610

PG1676

pckA

K01619

PG1996

deoC

K00763

PG0057

pncB

K01950

PG0531

nadE

bifunctional UDP-3-O[3-hydroxymyristoyl] Nacetylglucosamine
deacetylase/(3R)hydroxymyristoyl-ACP
dehydratase
UDP-3-O-[3hydroxymyristoyl]
glucosamine Nacyltransferase
tetraacyldisaccharide 4'kinase
3-deoxy-D-mannooctulosonic-acid
transferase
acyltransferase
glycerol-3-phosphate
dehydrogenase
glycerol-3-phosphate
cytidylyltransferase
phophomannomutase
fructose-1,6bisphosphatase
phosphoribosyltransferas
e/phosphoglycerate
mutase
pyruvate phosphate
dikinase
phosphoenolpyruvate
carboxykinase
deoxyribose-phosphate
aldolase
nicotinate
phosphoribosyltransferas
e
NAD synthetase

K00384

PG1134

trxB

thioredoxin reductase

K00945

PG0603

cmk

cytidylate kinase

Purine
metabolism/Pyrimidine
metabolism

K00525

PG1129

nrd

ribonucleotide reductase

Folate biosynthesis

K01633

PG2091

folB

K02342

PG1852

-

K02342

PG0223

-

K02919

PG1915

rpmJ

DNA replication
(DNA polymerase III)

Ribosome
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dihydroneopterin
aldolase
exonuclease (DNA
polymerase III subunit
epsilon)
exonuclease (DNA
polymerase III subunit
epsilon)
50S ribosomal protein
L36

K02916

PG0990

rpmI

K02895

PG1927

rplX

K02897

PG0167

rplY

K02876

PG1919

rplO

K02907

PG1920

rpmD

K02888

PG0314

rplU

K02904

PG1930

rpmC

K02952

PG1914

rpsM

K02956

PG1758

rpsO

K02996

PG0376

rpsI

K01886

PG1951

glnS

K01893

PG1121

asnC

K01876

PG0153

aspS

K04075

PG2046

-

K00566

PG0268

mnmA

Translation factors
(Elongation factors)

K02519

PG0255

infB

Protein export

K12257

PG1762

secDF

K00970

PG0801

-

K03595

PG2142

era

K03590

PG0583

ftsA

K03798

PG0047

ftsH

K03589

PG0582

ftsQ

K03569

PG1396

mreB

K03570

PG1395

mreC

K11753

PG0957

ribF

Aminoacyl-tRNA
biosynthesis (tRNA
synthetase)

(tRNA processing)

Chaperones and
folding catalysts
(Protein folding)
GTP-binding proteins

Chromosome
partitioning proteins
(cell division)

Cofactors

Riboflavin metabolism
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50S ribosomal protein
L35
50S ribosomal protein
L24
50S ribosomal protein
L25
50S ribosomal protein
L15
50S ribosomal protein
L30
50S ribosomal protein
L21
50S ribosomal protein
L29
30S ribosomal protein
S13
30S ribosomal protein
S15
30S ribosomal protein
S9
glutaminyl-tRNA
synthetase
asparaginyl-tRNA
synthetase
aspartyl-tRNA
synthetase
hypothetical protein:
tRNA(Ile)-lysidine
synthase
tRNA-specific 2thiouridylase MnmA
translation initiation
factor IF-2
bifunctional preprotein
translocase subunit
SecD/SecF
poly (A) polymerase
GTP-binding protein Era
cell division protein
FtsA
cell division protein
FtsH
cell division protein
FtsQ
rod shape determining
protein MreB
rod shape determining
protein MreC
riboflavin biosynthesis
protein RibF

interesting is the dual role the pathway plays in lysine and peptidoglycan biosynthesis, making
evident its potential for antimicrobial therapy. However, what makes lysine biosynthesis suitable
for species-selective targeting is the presence of pathway variants (Fig. 6). The pathway is
composed of four different branches, differing by the substrate intermediates at the branch point
of L-2, 3, 4, 5-tetrahydrodipicolinate’s (THDP) conversion to meso-diaminopimelate (m-DAP).
The succinylase branch utilizes succinyl-CoA to generate succinylated intermediates; similarly,
the acetylase branch utilizes acetyl-CoA to produce acetylated intermediates. These two variants
are used by the majority of Gram-negative and Gram-positive bacteria. The aminotransferase
branch, used by plants and methanococci, involves a single step amine transfer to produce the
precursor of m-DAP, LL-DAP [180]. However, for P. gingivalis, m-DAP [181-185] is directly
produced by meso-diaminopimelate dehydrogenase (m-Ddh; PG0806; GenBank ID:
AAQ65966.1) in a single step [181-185]. This led us to focus on m-Ddh as a potential target to
pursue. To further narrow selectivity, microbes from the Human Oral Microbiome Database
(HOMD) with an annotated m-Ddh were collected and aligned against m-Ddh in P. gingivalis.
Out of 315 sequenced genomes, 69 contained an ortholog to m-Ddh. Interestingly, these 69
species mostly included known pathogens such as Prevotella sp., Tannerella sp. and Veillonella
species. This indicated the target could be useful across multiple pathogens contributing to
periodontal diseases.
An important component in antimicrobial therapy is the ability to target critical biological
processes required for bacterial cell survival. Historically, these targets have focused on key
biological functions such as DNA replication, protein translation and cell wall biosynthesis
[186]. While m-Ddh is involved in protein and cell wall biosynthesis and we predicted the gene
to be essential, prior to the beginning of our study we did not know whether this was
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Figure 6. Variant pathways of lysine and meso-diaminopimelate biosynthesis.
Genes involved in the enzymatic reactions are omitted for general overview with the exception of the
dehydrogenase pathway. Figure adapted from Born et. al.

53

experimentally true. To verify m-Ddh was essential in P. gingivalis strain W83, we knocked out
the gene by transforming cells with a recombinant PCR product carrying an erythromycin
resistance cassette (ErmR) allowing for allelic replacement mutagenesis within the genome.
Through this method, the antibiotic resistance cassette replaces the target gene and, if essential,
results in non-viable cells following transformation. The disruption of the PG0806 gene with the
ErmR cassette resulted in no colony formation following electroporation and recovery in
selective media (Fig. 7a). This result was repeated independently; suggesting that deletion of
PG0806 is lethal to P. gingivalis and therefore essential. To show that the lack of colony
formation was in response to the essentiality of the gene and not problems with the
transformation, we simultaneously carried out allelic replacement mutagenesis for a nonessential hypothetical membrane protein (GenBank ID: AAQ65282.1). For this control we were
able to obtain substantial colony formation (Fig. 7b).
Another component for a potential target is “druggability” or the chance a small-molecule
will bind and have a significant effect on the protein’s activity [187]. Druggability can be
assessed in several methods, e.g., proof-of-concept in similar proteins, conserved or targetable
sequence motifs and structural analysis [188]. m-Ddh enzymes from several organisms
referenced in UniprotKB/Swiss-Prot with known or binding sites predicted by similarity were
aligned (Fig. 8). P. gingivalis has approximately 30% sequence identity to C. glutamicum, L.
sphaericus, C. thermocellum and U. thermosphaericus and 70% sequence identity to B. fragilis.
When analyzing the sequences of m-Ddh we found that the binding pocket for m-DAP was
highly conserved. Druggable proteins have been shown to consist of a higher ratio of non-polar
to polar amino acid residues (m-Ddh; 59.1% vs 40.9%) and a lower isoelectric point
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Figure 7. Allelic replacement mutagenesis for predicted essential gene target, m-Ddh.
(a) Predicted essential gene PG0806 was transformed and plated on selective media resulting in no colony
formation compared to (b) a non-essential gene control, validating the prediction that m-Ddh was
essential.
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(m-Ddh: 5.39 vs 7.44 in non-targets). Analysis showed that m-Ddh contains an oxidoreductase
domain, a favored targeted enzyme class [189] and which has been previously determine with
high confidence to be “druggable” by the Druggable Cavity Directory. Structural analysis by
SYBYL revealed a solvent inaccessible binding cavity with residues corresponding to the mDAP sequence alignment and the conserved motifs (Fig. 9). This binding cavity consists of a
relatively deep and hydrophobic region which should consist of hydrophobic amino acid residues
such as methionine, tryptophan and phenylalanine (Fig. 9). In addition, m-Ddh from C.
glutamicum has been co-crystallized in a complex with the endogenous substrate [190].
Therefore, m-Ddh structure appears to be “druggable”, making it a suitable target for drug
discovery.

Discussion
We aimed to present a quick and efficient manner to identify putative essential genes in bacterial
species lacking genome-wide experimental data. This would be of great benefit, especially
during drug discovery for emerging and re-emerging pathogens. Essential genes present novel
targets for overcoming antibiotic resistance and developing new antimicrobial drug therapies.
Genome-wide experimental efforts can be expensive and time-consuming, which has resulted in
an increase in predictive methodologies. We established a framework for a novel approach
derived from previous studies in a Gram-positive bacterium S. sanguinis [139]. We showed that
essential genes can be linked to pathways related to three basic biological categories allowing for
the prediction of essential genes based on gene function and annotation, subverting the need for
orthologous genes comparison.
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Figure 8. Sequence analysis of m-Ddh.
(a) Sequence alignment of m-Ddh from other bacterial organisms. The multiple sequence alignment
analyses were performed using the T-Coffee multiple alignment. Alignment figure was generated in
ESpript 3.0 The putative binding sites of Corynebacterium glutamicum (Cg), Lysinibacillus sphaericus
(Ls), Bacteroides fragilis (Bf), Clostridium thermocellum (Ct) and Ureibacillus thermosphaericus (Ut)
cited in the sequence annotations in UniProtKB/Swiss-Prot and P. gingivalis (Pg) predicted based on
homology are indicated by astericks. The oxidoreductase domain for P. gingivalis is indicated by arrows
below sequence. Secondary structure for P. gingivalis is annotated above the sequence. Relative
percentage of characterized amino acid residues are shown below. (b) Secondary structure alignment of
m-Ddh’s putative binding site from P. gingivalis (green), C. glutamicum (cyan) and U. thermosphaericus
(purple). Key residues are labeled, side chains are displayed as sticks and colored corresponding to atom
type. Hydrogens were omitted for clarity.
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Figure 9. 3D structural analysis of m-Ddh from P. gingivalis.
Ribbon based structure of m-Ddh with the m-DAP binding domain. m-DAP binding cavity is displayed by
wireframe surface and zoomed in view of cavity with corresponding a.a. residues labeled. Cavity colored
by hydrophobicity (red = hydrophobic) is shown below.
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In this study, we assessed the efficacy of our novel approach. By applying our gene
annotation prediction model to the Gram-negative periodontal pathogen, P. gingivalis, and
utilizing experimental data from a genome-wide transposon mutagenesis study performed in
strain W83 of P. gingivalis, we showed that: 1) our assessment of essential pathways and
knowledge of key genes within those pathways is accurate; 2) our model can easily be applied to
a variety of bacterial species; 3) our prediction model may identify a core set of essential genes
and provide important genomic data to refine our prediction model through the comparison of
experimental data; 4) the benefit of having a bioinformatics/predictive approach together with an
experimental approach; and 5) by applying our prediction model, we can accurately select a
potential antimicrobial drug target.
From 1909 protein encoding genes annotated in KEGG, we predicted 212 essential genes.
These genes fit within the three assigned biological categories (maintenance of the cell envelope,
energy production and processing of genetic information) reaffirming the backbone of our model
of essential genes. Having the advantage of recent experimental data by Klein et al., we
compared the two studies. The initial mutagenesis study was done in strain ATCC 33277 where
463 essential genes were identified. However, a new transposon mutagenesis study was carried
out in strain W83 for the direct comparison of essential genes. In this experimental study, 759
putative essential genes were identified and a comparison resulted in roughly an 81% match to
our model. It is important to note that the experimental data for strain W83 was not as
comprehensive as the study from strain ATCC 33277, which is why not all the genes within the
genome are accounted for. We also focused on what was determined to be putatively nonessential, to determine if we had false-positive predictions. From the study, 680 genes were
determined to be non-essential. Our model was also accurate in not predicting non-essential
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genes as essential. Only 7 genes were predicted from our model, but the majority (3 out of 5) had
isozymes or paralogs that were determined to be essential.
Several limitations of our essential gene prediction model should be noted. First, our
model does not identify hypothetical proteins as essential. Although hypothetical proteins may
present a subset of undiscovered gene targets, it is unlikely that all of these genes would encode
functions essential to the cell. During our experimental screen of S. sanguinis, out of 218
essential genes, only three were annotated as hypothetical. We also found that three of the
hypothetical proteins shown to be essential during the transposon mutagenesis should not be
expressed under the experimental conditions [191]. Genes not expressed may lead to false
positives in transposon or allelic replacement mutagenesis studies. Second, genes whose
functions are incorrectly annotated or incomplete will decrease the accuracy of our prediction.
This would lead to genes falsely predicted to be essential or missed during our analysis
completely. Organisms whose genome annotation is incomplete would also result in missed
prediction during our analysis. For example, the KEGG genome annotation of P. gingivalis W83
is missing key enzymes in glycolysis for the conversion of PEP to pyruvate and pyruvate to
acetyl-CoA. Another issue would be isozymes and/or paralogs. As our model is essentially
predicting single gene knockouts, it would be difficult to determine whether one or both genes
would be essential without experimental screening. Essential genes are predicted based on their
biological function in regards to essential pathways. Ubiquitous genes or genes whose function is
not linked to a specific pathway may be difficult to predict or may be missed. This is especially
true for genes involved in genetic information processing. Many of these genes are involved in a
variety of processes not defined to a specific biological functions. Lastly, genes can rarely be
classified as absolutely essential or non-essential as the definition greatly depends on the
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specified set of conditions [192]. Gene inactivation may result in a slow growth phenotype or a
cell with decreased fitness that will die over time. For instance, deletion of the pyrophosphatase
ppa gene in E.coli is viable for several hours until cellular pyrophosphates become too high,
stopping cell growth [193]. Our model also assumed P. gingivalis cells were grown during in
vitro conditions with rich media. Certain genes corresponding to the formation of vitamins and
co-factors were noted as non-essential as they would be provided to the cell by the medium.
Changes in these conditions, such as cells grown with minimal media, would therefore require
additional pre-cursor essential genes.
A considerable benefit to this essential gene prediction model is the ability to quickly
identify a set of potential drug targets. Due to the ease of our prediction, this method can be used
to compare data across different genomes. By understanding crucial biochemical pathways and
products, we could use model to identify species-selective essential genes as drug targets such as
with our comparison between S. sanguinis and P. gingivalis. By comparing alternative pathways
or differences in essential components (e.g., LTA versus LPS), we can identify specified
essential genes. Information garnered from the comparison of experimental data can provide
insight for our predictive model such as strain-specific essential genes. We aimed to support this
hypothesis by selecting m-Ddh as a species-selective target for P. gingivalis. When selecting a
drug target, it must not only be essential for the survival of the pathogen or disease virulence, it
must possess certain sequence and structural features and three, have assayable activity. As a
potential drug target, we were able to show through allelic replacement mutagenesis that m-Ddh
is an essential enzyme. Previous studies comparing sequence and structural data between targets
and non-targets showed druggable proteins are more likely to be of certain enzyme classes,
contain more non-polar amino acids and have a lower isoelectric point, indicating molecules
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more acidic in nature [189]. Based on these factors, m-Ddh is a “druggable” enzyme with a
sequence and structural motif that has the ability to be targeted by small-molecules.
In conclusion, we have developed an accurate method to quickly predict a core set of
essential genes through the analysis of gene function. While currently our data may not be
comprehensive, our results demonstrate that this method can accurately be applied to organisms
lacking experimental data. As genomic data and gene annotation becomes more complete our
prediction model will also, and we anticipate more biological functions of hypothetical genes
will be discovered with the advances of genome research. Further experimental data can also
narrow the function of those experimental essential hypothetical genes down to the three basic
biological categories that will increase discovery of gene functions. Additionally, more extensive
studies can refine our prediction of key differences in essential genes between organisms. For
example, many genes involved in fatty acid biosynthesis are essential for Bacillus subtilis and
Escherichia coli, but the pathway is incomplete in Mycobacterium genitalium, indicating the
product can be provided or is not essential [157]. This will ultimately facilitate our knowledge of
essential genes. Overall, our study verifies the validity of our previous findings and by applying
this to P. gingivalis we were able to identify m-Ddh as an essential and “druggable” target for the
treatment of periodontal disease.
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Chapter Two
Combinational Computer-based Drug Discovery to Identify SmallMolecule Inhibitors against meso-diaminopimelate dehydrogenase
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Background
Historically, antimicrobial drug discovery involved high-throughput screening of thousands of
compounds for inhibitory activity, followed by secondary assays to identify the mechanism of
action [97, 194]. Unfortunately, this was time consuming and costly, requiring on average 15
years and $800 million [96, 195]. Coupled with a low success rate, this investment prompted a
decline in antibiotic research by pharmaceutical companies, leading to a lack of new and
effective drugs entering the market [126, 194]. However, with resistance and re-emerging
pathogens on the rise, new approaches in drug development are critical for the future of
antibiotics.
Recent advances in genomics, structural biology and computational chemistry have
provided alternative strategies to traditional methods, giving rise to rational drug design [196].
The principle of rational drug discovery involves identifying or designing compounds based on
the target’s biological features. Consequently, the validation of a potential target is an important
first step. We have previously demonstrated the understanding of essential gene functions can
allow for the rapid prediction of essential genes as potential antimicrobial targets [139]. This
understanding coupled with the knowledge of alternative pathways and differing metabolic
requirements can be used to identify unique or species-limited gene targets. With a validated
target, computer-based drug discovery (CBDD) can be a rapid, efficient and inexpensive way to
identify and obtain a selection of potential antimicrobial compounds.
The use of a combinational CBDD approach (i.e., pharmacophore model, structure-based
virtual screening (SBVS) and molecular docking/scoring) has been shown to be advantageous to
the drug discovery process in many systemic disease studies, increasing their hit and success rate
[197-199]. Due to the increasing access of essential genes (i.e. the DEG) [163] and protein
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crystal structure data (i.e. PDB) [200] it has recently begun to be applied to antimicrobial
research. A previous study in M. tuberculosis strain H37Rv successfully employed a multi-step
screening strategy, combining modeling, SBVS and docking to identify a potent inhibitor against
MtCM, a chorismate mutase [201]. Using a pharmacophore model we can generate a virtual
description of molecular features essential to the desired protein-ligand interaction [202] based
on observed experimental or in silico interactions [203]. This pharmacophore model can then be
used for SBVS, which can replace costly and time-consuming experimental HTS assays. For
SBVS a database with the structural data of millions of compounds is screened against the target
protein to identify those that fit within the defined features and molecular docking is used to
calculate and rank the binding mode for the select ligands within a defined region. Docking and
scoring is a crucial step in CBDD. By defining an ideal pose, docking can aid in minimizing
false positives prior to experimental studies and later can be integral in structure optimization
[202]. However, evaluation of the optimal docking pose can vary based on the specific program
and algorithm. For example, Goldscore uses a force-field method (summation of van der Waals
and electrostatic interactions) [204] compared to CHEMPLP which utilizes empirical free energy
scoring (enumeration of various types of interactions) [205]. To minimize the potential bias,
studies suggest rescoring with different algorithms to determine the optimal binding
confirmation [202]. As an additional means to evaluate the protein-ligand interaction, the free
energy for optimal binding position can be predicted. HINT (Hydropathic INTeractions),
developed by Kellogg and Abraham [206], is an empirical force field based on experimental
measurements of the small molecule partition coefficient, Log Po/w. Since Log Po/w is
thermodynamically related to free energy, the HINT score corresponds to the free energy of
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intermolecular binding interactions. The combination of these approaches can provide a
promising start for a novel antimicrobial drug discovery project.
We aimed to use periodontal disease and the keystone pathogen, P. gingivalis as an
exploratory model for pathogen-specific drug targeting. We identified m-Ddh from P. gingivalis
as a species-selective, essential and druggable target. The m-Ddh crystal structure from P.
gingivalis (PDB ID: 3BIO) [207] was determined as part of the Protein Structure Initiative in
2007 [207, 208] allowing us to apply a combinational CBDD strategy to identify small-molecule
inhibitors. In this study, we generated a pharmacophore model based on the natural substrate and
previous m-Ddh inhibitor studies from B. subtilus and C. glutamicum [209]. We go on to adopt a
HTS virtual screening method utilizing the ZINC drug-like database of commercially available
chemicals to identify small-molecule inhibitors. Finally, we docked and scored the HTS results
to identify a subset of high-ranking compounds as the initial steps in developing a novel strategy
for antibiotic drug discovery.

Materials and Methods
Molecular modeling.
Protein structure. The structure of meso-diaminopimelate dehydrogenase (oxidoreductase,
Gfo/Idh/MocA family member) from P. gingivalis strain W83, was crystallized as part of the
National Institute of Health-National Institute of General Medical Sciences (NIH-NIGMS)
sponsored Protein Structure Initiative (http://www. nigms.nih.gov/Initiatives/PSI/) [210, 211]
and was solved at a resolution of 1.80 Å. The crystal structure data was downloaded from the
Protein Data Bank (PDB ID: 3BIO) [207] and applied in our study. The binding site was
identified by sequence homology to the ortholog in C. glutamicum, whose crystal structure was
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previously determined in a complex with the substrate, meso-diaminopimelate (m-DAP), in the
binding pocket (PDB ID: 2DAP) [190]. Using Sybyl X.1 (Tripos, St. Louis, MO), the protein
was prepared for virtual screening and docking studies by extracting water molecules and cocrystallized ligands and deleting one of the two monomers. The pKa values of the amino acid
residues within the binding pocket were predicted and the appropriate ionization states were
assigned in SYBYL for a pH 10.5 based on the conditions of the in vitro enzymatic experimental
assay. Appropriate atom types were assigned, hydrogens were added and the protein was
minimized with Sybyl’s Tripos force field.
Structure-based virtual screening. Virtual screening was performed with the UNITY module
within the Sybyl-X molecular modeling program Unity uses a directed tweak algorithm [212] to
simulate molecular flexibility while screening small molecules. The binding pocket of m-Ddh
was used as the target site, by constructing a variety of queries based on the pocket’s properties.
Over 9 million small molecules were screened in silico from ZINC [213] drug-like databases
(http://www.zinc.docking.org).
Molecular docking. Docking and two-step scoring was used to evaluate the results of virtual
screening. By visually inspecting and filtering the UNITY hits, we selected the top 132 smallmolecule compounds for further computational analysis. We used GOLD (Genetic Optimization
Ligand Docking) docking program v5.2) [204], targeting the binding site of in m-Ddh. A sphere
with radius of 12 Å from Arg183 was set as the docking region. This allowed for the inclusion of
all residues expected to be within the binding site. The protein model was prepared for docking
as described above. Conformational flexibility was allowed for the small molecules. We allowed
for 50 GA (Genetic Algorithms) runs with a distance of 1 Å between clusters. The 132
compounds selected from our virtual screening hits were docked by GOLD, ranked by Goldscore
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and then re-ranked by the CHEMPLP as implemented in GOLD. All docked compounds were
then scored in a second pass by HINT (Hydropathic INTeractions) [214]. The binding mode
corresponding to the highest-ranking HINT score for each compound was chosen as the best and
most likely conformation for that compound. From these 132 compounds, the top 30% of the
best-scored, structurally diverse compounds as ranked by HINT were re-docked and minimized
with 10,000 iterations within the m-Ddh binding site. Finally, out of forty top scored small
molecules, 11 compounds were commercially available and were purchased for assay. All
images were generated in Pymol (http://www.pymol.org).
Cloning, expression and purification of m-Ddh. The amino acid sequence of m-Ddh from P.
gingivalis was codon-optimized for expression in E. coli cells, synthesized and cloned into a
pUC57 vector by GenScript (Piscataway, NJ). To introduce the 6×-HIS tag to the C-terminal end
of the gene, the plasmid was digested at NdeI and NotI restriction sites. The digested fragments
were loaded onto a 1% agarose gel and purified using MinElute® Gel Extraction kit (Qiagen,
Valencia, CA). The purified DNA insert was ligated into a NdeI- and NotI-digested pET-21a (+)
vector (Merck Millipore, Billerica, MA) by T4 DNA ligase (New England Biolabs, Ipswich,
MA), yielding the expression plasmid pET-Ddh. The plasmids containing the DNA construct
were isolated using QIAprep® Spin Miniprep plasmid (Qiagen, Valencia, CA) and sequenced at
VCU Nucleic Acids Research Facilities (Richmond, VA).
The pET-Ddh plasmid was introduced into E. coli BL21 (DE3) pLysS (BioLine,
Taunton, MA) and grown overnight in auto-inducing media ZYP5052 containing 100 µg/ml
ampicillin at 37 ˚C. For purification, cells were disrupted by Emulsiflex C3 high pressure
emulsifier (Avestin, Ottawa, Canada). Soluble protein was collected and separated from cell
debris by centrifugation (20, 000 × g for 20 mins at 4 ˚C). The resulting supernatant was loaded
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onto a NTA-Ni2+ affinity column (Qiagen) pre-equilibrated with running buffer (25 mM Tris,
300 mM NaCl, 10 mM imidazole, pH 8.0). Unbound protein was washed off with wash buffer
(25 mM Tris, 300 mM NaCl, 10 mM imidazole, pH 8.0) and chelated protein was eluted off with
elution buffer (25 mM Tris, 300 mM NaCl, 100 mM imidazole, pH 8.0). Protein concentration
was calculated based off of absorbance at 280 nm.
Molecular mass analysis of purified m-Ddh. The enzyme was examined by 12.5% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) stained with Coomassie Blue
G-250 (Bio-Rad, Hercules, CA). Samples were boiled in 2X Laemmli buffer (4% SDS, 10% βmercaptoethanol, 20% glycerol, 0.125M Tris-HCl, 0.004% bromophenol blue).
The molecular weight of the native enzyme was determined by gel filtration
chromatography. Gel filtration was carried out using an Äkta Pure Protein Purification System
(GE Healthcare, USA) with a 1 ml injection loop. The column was calibrated using Gel filtration
protein standards of molecular weights ranging from 12,000 – 200,000 Da: standards 1, βamylase (200 kDa) and cytochrome c (12.4 kDa); standards 2, alcohol dehydrogenase (150 kDa)
and carbonic anhydrase (29 kDa); standards 3, albumin (66 kDa). 500 l of a 3.2 mg/ml purified
protein was run through a Superdex 75 10/300 GL column (GE Healthcare, USA) at an elution
rate of .5 ml/min with a 25 mM Tris-HCl, 300 mM NaCl, 100 mM imidazole buffer (pH 7.5)
elution buffer. Fractions of 1ml volume were collected. Fractions were then analysed by
spectrophotometry. Protein size was calculated by standard curve of molecular mass vs. Ve
(elution volume)/Vo (void volume) for each protein standard.
m-Ddh kinetic assay. The enzymatic activity for m-Ddh was determined by observing the
standard oxidative deamination reaction of the substrate meso-diaminopimelate [215]. The
reaction contained 400 µM of meso-diaminopimelate (Sigma-Aldrich, St. Louis, MO), 180 µM
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NADP+ (Sigma-Aldrich, St. Louis, MO), 200 mM glycine-KCl-KOH buffer (pH 10.5), and the
enzyme in a final volume of 1 ml. The reaction was initiated with the addition of NADP+. The
reaction velocity was calculated from the increase in absorbance at 340 nm,
spectrophotometrically monitored at 25 ˚C, where one unit of enzyme was defined as the amount
of enzyme catalyzing the formation of 1 mmol of NADPH per min.
Determination of kinetic parameters. Initial velocity measurements for m-DAP and NADP+
were determined at 25 ˚C in a similar reaction for the standard oxidative deamination reaction
assay. The reaction contained 200 mM glycine-KCl-KOH buffer (pH 10.5) with m-DAP as the
variable substrate with concentrations between 0.001 mM and 1 mM and NADP+ held constant
at a saturating concentration of 0.5 mM or NADP+ as the variable substrate with concentrations
between 0.01 mM to 1 mM and m-DAP held constant at 0.5 mM. Km and Vmax values were
determined through non-linear fitting. All assays were performed in triplicates and non-linear
fitting Michaelis-Menten data were calculated from Graphpad Prism v5.04 (Graphpad, San
Diego, CA).
Mutagenesis of m-Ddh. For site directed mutagenesis, pET-Ddh plasmid was used as a template
for single residue site-directed mutagenesis of m-Ddh (R183Y, R183K, D124E and D124A). The
phosphorylated primer set for each mutant was as follows. Forward R183Y: 5’- ACG GGT GTG
CAT CGT TAT ATG GTC TAT GTG GAA-3’ and Reverse R183Y: 5’- TTC CAC ATA GAC
CAT ATA ACG ATG CAC ACC CGT-3’; Forward R183K: 5’- ACG GGT GTG CAT CGT
AAA ATG GTC TAT GTG GAA -3’ and Reverse R183K 5’- TTC CAC ATA GAC CAT TTT
ACG ATG CAC ACC CGT-3’; Forward D124E: 5’- C GCA TCA GGC TGG GAA CCG GGT
AGT GAT TCC-3’ and Reverse D124E: 5’- GGA ATC ACT ACC CGG TTC CCA GCC TGA
TGC G -3’; Forward D124A: 5’- ATC AGG CTG GGC GCC GGG TAG TG -3’ and Reverse
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D124A 5’- GCG ATA ACC GCA GCT GCA -3’. All PCR reactions were performed with an
initial denature of 98 ˚C for 30 sec, 25 cycles of 98 ˚C for 10 sec, 56 ˚C for 30 sec, 72 ˚C for 2
min 45 sec and a final extension of 72 ˚C for 7 min. PCR products were digested with 1 U of
DpnI (New England Biolabs, Ipswich, MA) at 37 °C for 1 h and inactivated for 20 min at 80 °C.
The plasmids containing the mutation were sequenced at VCU Nucleic Acids Research Facilities
(Richmond, VA). The final product was used to transform into E. coli DH5α T1 competent cells.
Phusion High-Fidelity Taq DNA polymerase (New England Biolabs, Ipswich, MA) was used in
all reactions. Mutants were transformed, expressed and purified as previously described for WT.

Results
In silico analysis of m-Ddh structure and function. The enzyme catalyzes the NADP+
dependent oxidative deamination of m-DAP (Fig. 10). The reaction is reversible and the
biologically favored reaction involves the NADPH dependent conversion of L-2,3,4,5-THDP to
m-DAP by reductive animation. During this reaction L-2,3,4,5-THDP first has a spontaneous
ring opening to produce L-α-amino--ketopimelate. L-α-amino--ketopimelate catalyzed by mDdh generates an imine intermediate before yielding m-DAP. Crystal structure data suggests the
protein is similar to previously studied m-Ddhs [182, 216-218]. It is a homodimer and sequence
analysis indicates it consists of three main domains: a NADP+-binding domain which
corresponds to the conserved GXGXXG sequence found within the N-terminal βαβ-protein fold
[219], a dimerization domain and an oxidoreductase domain (Fig. 11). Studies in C. glutamicum
and B. sphearicus show that m-Ddh has a strict specificity for the D-amino acid center of m-DAP
being placed near the NADP(H) domain [220-222].
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Figure 10. Schematic for the m-Ddh catalyzed biochemical reaction.
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To assess the binding model of the natural substrate within the protein pocket we docked
m-DAP (Fig. 12). The protein was prepared as described in “Materials and Methods” and we
used GOLD docking program v5.2, selecting the 9 a.a. residues previously predicted to be the
binding site as the area of the docking region. m-DAP binds within a deep groove situated so that
the two carboxylate groups face the protein side allowing for hydrogen bond interactions
(Arg183, Thr173, Met154 and Gly155). The two amine groups face away from the protein
allowing for potential solvent interactions. The positioning places the D-amino acid center near
the NADP+ binding site to allow for the hydrogen exchange and the enzymatic reaction to occur.
This binding mode corresponded to what has been observed in crystal data studies [190, 220].
In vitro analysis of m-Ddh structure and function. To first confirm the structural and
functional in silico analysis of m-Ddh, we synthesized the gene and expressed it in E. coli. The
gene sequence encoding for P. gingivalis m-Ddh was codon-optimized and cloned into a T7
pET-21a (+) expression vector carrying a C-terminal 6x HIS tag. The protein was isolated
following the expression and purification described in “Materials and Methods”. The protein is
301 a.a. residues with a calculated molecular weight of 32 kDa, corresponding to the migration
of the monomeric structure on SDS-PAGE (Appendix, Supp. Fig. 2a). The crystallized structure
of m-Ddh from P. gingivalis indicated that the enzyme exists as a homodimer, the native
molecular weight was determined by gel filtration chromatography where two prominent peaks
eluted similarly to standard 3 (Appendix, Supp. Fig. 2b) at a calculated size of 66 kDa,
demonstrating that the active enzyme exists as a dimer.
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Figure 11. Structural domains of m-Ddh from P. gingivalis.
Dimer (top) and monomer (bottom) structure of m-Ddh from P. gingivalis. Structure consists of three
main domains which are highlighted by different colors. The substrate or oxidoreductase domain
(yellow), the dimerization domain (green) and the NAD(P) domain (blue). The NADP domain found in
the N-terminal sequence of m-Ddh corresponds to the conserved GXGXXG sequence within a
structural motif. 3D structure of m-Ddh was generated in Pymol (http://www.pymol.org). m-DAP docked
within the binding pocket is shown in pink.
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Figure 12. Molecular docking analysis of m-DAP binding model.
GOLD was used to dock the natural substrate, m-DAP into the predicted binding pocket of m-Ddh. The
optimal binding model determined by HINT score is displayed above (pink). Binding position of m-DAP
from previous crystal data studies (PDB ID: 2DAP) is overlaid with predicted docking model (yellow) to
show similar binding. NADP+ docked in its binding pocket is shown below to display the positioning for
the hydrogen exchange and the enzymatic reaction. Key residues for intermolecular interactions are
labeled, displayed as ball and sticks and colored corresponding to atom type. Hydrogens were omitted for
clarity. Potential hydrogen bonding interactions between m-Ddh and a.a. residues are shown by yellow
dashed lines.
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We next examined the Michaelis kinetics to evaluate the activity of the enzyme and
determine the kinetic parameters for the oxidative deamination of m-DAP. This reaction is
spectrophotometrically observable at 340 nm. This allowed for the development of a standard
screening assay, monitoring the reduction of NADP+ to NADPH. Analysis of the initial velocity
showed typical Michaelis-Menten kinetics (Fig. 13). The apparent Km and Vmax for m-DAP was
determined to be 370 M and 130 nmol sec-1 and 60 M and 92 nmol sec-1 for NADP+ (Fig. 13)
respectively.
Docking studies indicated that the carboxylate groups were essential for the binding
through hydrogen bonding interaction. To verify this we selected Arg183 to mutate with a
favored residue substitution or an un-favored substitution (Table 3; Fig. 14a). An Arg mutation
to an un-favored substitution (R183Y) resulted in a significant decrease in substrate affinity (35fold increase in the apparent Km) compared to WT but retained similar catalytic efficiency. This
was in contrast to the favored Arg substitution (R183K) which maintained similar Km and
Kcat/Km values as the WT. Comparison of these two mutants with the WT docking showed a loss
in a favorable hydrogen bonding between R183 and m-DAP during the Y183 mutation which led
to a decrease in the calculated HINT interaction. Mutant R183K had a similar pose as WT,
reflected by a strong HINT interaction between the carboxylate group of m-DAP and the amine
group from K183. Asp124 is positioned within the protein for both NADP+ and m-DAP
interaction. A favored mutation (D124E) resulted in a slight increase in substrate affinity (2.7fold decrease in the apparent Km) and an increase in catalytic efficiency. In contrast, the D124A
mutation had a dramatic change in both the apparent Km and the catalytic efficiency resulting in
almost no measurable activity (Table 3; Fig. 14b). Docking showed similar potential hydrogen
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Figure 13. Kinetic analysis of purified m-Ddh from P. gingivalis strain W83.

Characterization of kinetic properties of m-Ddh. Oxidative deamination reactions were
performed in the presence of increasing concentrations of (a) m-DAP as the variable substrate
with NADP+ fixed at a saturating concentration or (b) NADP+ as the variable substrate and mDAP held constant. Km and Vmax values were determined through non-linear fitting.
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Table 3. Kinetic analysis of m-Ddh mutants.
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Figure 14. Site-directed mutagenesis of binding pocket.
GOLD was used to dock the natural substrate, m-DAP into m-Ddh with single a.a. substitutions of the
predicted binding pocket. The optimal binding model is displayed above. (a) Arg183 mutated to R183Y
left and R183K right with m-DAP docked. (b) Asp124 mutated to D124E left and D124A right with mDAP docked. Key residues for intermolecular interactions are displayed as ball and sticks and colored
corresponding to atom type. Mutated residues are labeled in red. The optimal m-DAP docked for WT mDdh is shown in pink to highlight changes in binding confirmation. Changes in potential hydrogen
bonding interactions that would affect activity is displayed as a dashed yellow lines. Hydrogens were
omitted for clarity.
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bonding for the D124E mutant, however there was a more favorable acid-base interaction
compared to WT. Conversely, D124A showed a slightly unfavorable base-base interaction
between the carboxylate group of m-DAP and the backbone of Asp.
Generation of pharmacophore model. To identify a binding model for inhibition, we searched
the literature for known inhibitors. Unsaturated analogues of m-DAP, containing a planar αcarbon and lacking the active D-amino acid amine center of m-DAP have been shown to be
strong inhibitors of m-Ddh isolated from Bacillus sphaericus and C. glutamicum [209]. It was
assumed the analogue inhibitors bind in manner opposite to that of the substrate; thus, the nonreactive L-amino acid center is positioned near the C-4 position of the co-substrate NADP+. This
would prevent the oxidation reaction and hydride exchange that normally would occur between
the substrate and co-substrate. We obtained two of these previously reported compounds; testing
in vitro showed dose-dependent inhibition against m-DAP from P. gingivalis.
The X-ray crystal structure was modeled and the unsaturated analogue inhibitors
(Compounds 1 – 3) as well as the m-DAP substrate were docked into the m-Ddh binding pocket
to identify the features that should be important for inhibitor interactions (Fig. 15a). The docking
model which best fit the expected in vitro interaction and displayed high docking scores was
used to generate a pharmacophore model. Based on the best ranking interaction, the
pharmacophore model focused on four features that were shared between the inhibitors and
substrate: 1) a hydrophobic region complementary to amino acid residues Trp123 and Phe148; 2)
a ligand donor atom complementary to residues Asp94 and Asp124; 3) a negative (acceptor)
center complementary to the side chain of residue Ser153 and the backbone of residues Met154
and Gly155; and 4) a negative (acceptor) center complementary to the side chains of residues
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Figure 15. Generation of pharmacophore model.
(a) Structure of m-DAP and inhibitor analogs that were previously shown to be active against m-Ddh in
C. glutamicum and B. sphaericus. (b) Compounds docked into m-Ddh binding site and conserved
interactions were identified. (c) Pharmacophore model with selected core features for inhibitor
identification during virtual screen. The model focused on four features: first, a hydrophobic region
complementary to amino acid residues Trp123 and Phe148 (green), second, a ligand donor atom
complementary to residues Asp94 and Asp124 (purple), third, a negative center complementary to the
side chain of residue Ser153 and the backbone of residues Met154 and Gly155 (red) and fourth, a
negative center complementary to the side chain of residues Arg183 and Thr173 (red). The interaction
was also restricted for an area 12Å in distance for Arg183. Key residues are labeled, displayed as ball and
sticks and colored corresponding to atom type. Hydrogens were omitted for clarity.
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Arg183 and Thr173. The interaction was also restricted to a sphere of radius 12 Å centered
around Arg183. This was because from our docking model Arg183 was seen to form hydrogen
bonds with the carboxylate groups of the substrate analogues and site-directed mutagenesis
decreased the substrate-protein binding affinity by 32-fold.
High-throughput virtual screening for identification of small-molecule inhibitors. The
pharmacophore model shown in Figure 15b was used in a high-throughput virtual screen of the
ZINC 3D database to identify small-molecule inhibitors that would fit the query constructed
from the pharmacophore. ZINC (Zinc Is Not Commercial) is a publicly available listing of
molecules that are reportedly available for purchase, organized in a manner appropriate for
virtual screening studies. In simple terms, a compound was classified as a hit if it fit all of the
features defined as mandatory in the model. The screening of more than 9 million compounds
within the ZINC database resulted in more than several hundred hits. Since the goal of virtual
screening is to identify unique compounds and scaffolds that have the potential to be developed
into active inhibitors, a filter was applied to remove compounds within the hit list too structurally
similar to one another. The resulting list was then filtered for drug likeness (i.e., with algorithms
based on Lipinski’s Rule of Five [188]) to remove compounds and scaffolds that were unlikely
to have reasonable physiochemical properties.
Molecular docking and scoring of small-molecule inhibitors. Compounds passing through
these filters were then docked to the binding site of m-Ddh with GOLD (Genetic Optimization of
Ligand Docking) program to predict their binding affinities and to assess the modeled
compound-protein interactions. Prediction of the best fit binding model of each compound, again
within 12 Å of Arg183, was determined and scored by Goldscore. The models with top docking
scores were re-docked to the binding site with the same docking parameters and rescored by
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CHEMPLP. A filter based on binding pose was applied and compounds that interacted
favorably, mostly via hydrogen bond, with the key residue Arg183 were identified. This filter
yielded 132 hits, which were then scored by the HINT force field. The binding mode
corresponding to the highest HINT score for each compound was then re-docked and minimized
within the m-Ddh binding site. From these 132 compounds, the top 30% of the best HINTscored, structurally diverse compounds were set-aside as the 48 final hits. Finally, samples of the
commercially available compounds in this group were purchased for future screening assays.
The HINT scores and compound structures of each of these 11 compounds (4 – 14) are shown in
Table 4.
In silico analysis of binding confirmations. The optimal binding pose for the six top ranking
compounds determined by HINT score are shown in Figure 16. The protein-inhibitor interaction
involved potential hydrogen bonding interactions with the backbone for Met154, Ser153 and
Gly155. The majority of the compounds possessed aromatic structures forming favorable
hydrophobic interactions with Phe148 or Trp123. The sulfonamide functional group on
compound 4, 5 and 6 show potential hydrogen bonds with Arg183 and Thr173. Due to distance
few compounds show potential hydrogen bonding with the Asp functional group. The exception
was compound 10 which lost hydrogen bonding between Arg183 and Thr173 to gain favorable
hydrogen bonding interactions with Asp93. Overall, these compounds maintained the desired
interaction determined through the pharmacophore model.
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Table 4. 2D structures and scoring of top-ranking compounds

Structure

HINT

Compound 4

3112

Compound 5

3014

Compound 6

2876

Compound 7

2095

Compound 8

4379

93

Compound 9

2569

Compound 10

4274

Compound 11

2344

Compound 12

1989

Compound 13

4190

Compound 14

1692

94

95

Figure 16. Optimal binding mode for top-ranking compounds.
Optimal binding model for the top-ranking compounds determined through HINT are shown above (see
Table 4). Key residues are displayed as ball and sticks and colored corresponding to atom type. Residues
labeled in the bottom middle figure correspond to all figures. Hydrogens were omitted for clarity.
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Discussion
Novel therapeutics have not kept paced with the need to overcome antibiotic resistance and fight
new and re-emerging pathogens. Traditional methods principally relied on empirical screening,
screening large numbers of compounds for whole-cell activity, flushing out the mechanism of
action and verifying the feasibility of the target later. This resulted in a costly and timeconsuming endeavor that was especially discouraging for small startups and academia which
lack the resources of larger pharmaceutical companies. In addition, as the ‘golden era’ of
antibiotic discovery waned, this approach proved ineffective. However, steady advances in
computational chemistry, protein chemistry and genomics have resulted in successful drug
discovery through CBDD for systemic diseases such as cancer [202]. Utilizing a combination of
CBDD techniques, a better understanding of a target can be gained, the properties essential for
the activity or inhibition assessed and a diverse set of inhibitors identified.
In this study, we aimed to present a rationalized approach to antibiotic drug discovery.
We employed a combinational CBDD approach which incorporated pharmacophore models,
SBVS and molecular docking. Ultimately screening more than 9 million small-molecule
compounds to identify potential inhibitors against P. gingivalis and utilize a novel approach in
antimicrobial drug discovery. By applying this method to the Gram-negative periodontal
pathogen, P. gingivalis, we showed that: 1) we can accurately assess the structure/function of our
target through computer-based molecular modeling; 2) we can identify key molecular features
for inhibitor screening; and 3) utilizing several CBDD techniques in parallel can lead to a rapid
selection of inhibitors.
The crystal structure data of m-Ddh was used to first examine the structure and related
function of the enzyme. The enzyme is an active homodimer that binds m-DAP and NADP+
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within close proximity at the N-terminus of the protein. It has been shown to have strict
specificity for the substrate which must bind in a certain orientation. This would allow for
specific hydrogen bonding interactions with the carboxylate groups of m-DAP. It also positions
the catalytically active amine group near the NADP+ moiety. As m-Ddh from P. gingivalis has
not been characterized in vitro, we expressed and purified the protein from E. coli. Gel filtration
analysis confirmed the assumed tertiary confirmation consistent with other characterized mDdhs. Previous studies of m-Ddh and its role in lysine biosynthesis have focused on the enzyme
from Corynebacterium [190], Bacillus [184], and Ureibacillus [217]. However, prior to our
study there was no enzymatic data on m-Ddh in P. gingivialis available. Therefore, we
determined the kinetic properties through the assessment of the enzyme assay. Analysis of the
kinetic data showed a Km value of 370 M with a Vmax of 130.1 nmol sec-1 for the substrate mDAP and a Km of 60 M with a Vmax of 91.95 nmol sec-1 for NADP+. We next used site-directed
mutagenesis to further evaluate the in silico interaction. The side chain of Arg183 was shown to
form hydrogen bonds within the active site. Mutation of Arg183 to Tyr was still catalytically
active but showed a large decrease in substrate binding compared to the WT. This may indicate
the replacement of Arg to the aromatic structure of Tyr may prohibit m-DAP access into the full
length of the active site but still allows for the enzymatic reaction near the D-amino center. D124
is found within the overlap between the substrate and co-substrate binding sites. Asp residues
within active sites are known to form stabilizing hydrogen bonds through salt bridges [223]. The
Ala substitution left the enzyme almost inactive. However a Glu substitution, which is similar to
Asp in structure and function, slightly increased the binding and efficiency. This could indicate
D124 may play an essential role in m-Ddh protein stabilization.

98

By analyzing the binding model of substrate analogue inhibitors we were able to define a
pharmacophore model with consistent features between three inhibitors and the substrate. Our
four key features mainly focused on the potential hydrogen bonding interactions. First identified
was a hydrophobic region from the aromatic residues Trp123 and Phe148. This interaction would
allow for another ring within that region and lead to potential hydrophobic stacking interactions.
The second feature, a ligand donor atom complementary to residues Asp94 and Asp124 would
allow for hydrogen bonding between the carbonyl oxygen groups. The third feature is a negative
(acceptor) center complementary to the side chain of residue Ser153 and the backbone of
residues Met154 and Gly155. The backbone of these residues would allow for potential
hydrogen bonding with the ligand acting as a hydrogen acceptor. The last feature was a negative
(acceptor) center complementary to the side chains of residues Arg183 and Thr173. This feature
is similar to feature three but involves the side chains for potential bonding. This characterization
allowed for the application of a rational HTS strategy utilizing the ZINC compound database.
Compounds identified were then subjected to docking analysis through GOLD and two distinct
scoring approaches. This resulted in more than 100 compounds. Finally a subset of the
commercially available compounds which were computationally determined to be the best fit
were selected for future in vitro analysis.
In conclusion, we have successfully applied a CBDD method to identify a select group of
structurally diverse small-molecule compounds against m-Ddh. While currently this data is
preliminary, our results demonstrate that this multifactorial method can accurately be applied to
antimicrobial drug discovery and due to the feasibility, can be used across a variety of infectious
pathogens. In addition, the rational selection and preliminary in silico screening should lead to a
higher success rate than traditional trial and error experimental screening. This study may also
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present a better understanding of our validated target. Through computational modeling we can
further study the structure of the protein. This is important, as molecular features correspond to
the activity of the protein and by understanding these features a compound can then be selected
or designed to interact against these features. Ultimately, this may result in a more in-depth
pharmacophore model, improved HTS drug screening or structural optimization of active
inhibitors. Overall, our study presents the rationale for this approach and by applying this to P.
gingivalis we were able to identify potential inhibitors for the treatment of periodontal disease.
Coupled with further experimental data we can verify our computational analysis and this should
aid in the progression of an antimicrobial drug discovery model.
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Chapter Three
In vitro Characterization of Small-Molecule Inhibitors against mesodiaminopimelate dehydrogenase

Victoria N. Stone and Ping Xu

Victoria N. Stone performed the experiments, the analysis of data and the preparation of the
following manuscript. Dr. Ping Xu acted as an advisor.
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Background
Undoubtedly, CBDD is an exceptional way to identify a set of inhibitors against a specific target.
The rational assessment of potential interactions allows for the selection of small molecules with
a higher probability of binding, thereby increasing the efficiency of HTS [202]. However, their
activity is based on computational algorithms and is therefore theoretical. It does not provide
information on the potency, pharmacokinetics or cytotoxicity. Before inhibitors identified in this
manner can progress into potential antimicrobials, it is necessary to evaluate the defined activity
through an in vitro screening phase. Primarily, this consists of two general biochemical
methodologies: target-based to assess protein-inhibitor interaction and cell-based to screen for
whole-cell growth effects [224].
Target-based screening assays are used to verify the inhibitor binds the identified target
and has a significant effect on its activity. First, it is important the target can be isolated,
characterized and a suitable assay can to be developed that is simple and cost-effective while
being sensitive enough to detect changes in activity [122]. This is to ensure that the assay is able
to screen a large amount of small molecules and the results are reproducible. With our target, mDdh, purified and enzymatically characterized, we determined a standard enzymatic assay for
screening. The reduction of the co-factor NADP+ to NADPH is monitored at 340 nm by
spectrophotometric analysis and the rate of that reaction determined. Inhibition can then be
defined by the corresponding changes in the enzymatic rate. This screening strategy is similar to
the HTS performed by GSK for the identification of inhibitors against two enoyl-ACP reductase
enzymes, FabI and FabK [126]. By monitoring the consumption of NAD(P)H, an inhibitor
displaying slight in vitro activity was identified and later optimized for whole-cell activity [225,
226]. Observed target inhibition is used to relate potential pharmacodynamics and
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pharmacokinetics of the inhibitor by constructing a dose-response curve. This is used to observe
the effect that different concentrations have on the enzyme activity, generating the concentration
at which half the enzyme activity is inhibited (IC50) [227]. The IC50 allows for the assumption
that the inhibition is directly correlated to the inhibitor (non-toxic). Further target-based assays
during this stage lead into target-related mechanism of action studies, such as defining the
inhibition pattern and binding affinity. Additionally, this data provides the relative inhibitor
activity and combined with structural analysis outlines the initial SAR studies [228]. Ultimately,
this can be used to understand which parts of the ligand can be altered to improve activity or the
pharmacodynamics.
One of the most essential properties of an antibiotic is the ability to cross the membrane
and exert a biological effect on the cell. However, inhibitors that show activity against a target
may not possess the optimal structural properties for whole cell activity. Whole-cell based assays
are used to determine whether a small molecule possess antimicrobial properties. MICs, defined
as the lowest concentration that inhibits cell growth, are typically used as a cell-based method to
relate inhibition to activity. However, it is important to connect whole-cell activity with a target’s
inhibition or in other words verify the MoA [229]. This can involve the alteration of the intended
target such as over- or underexpression of the target [230], transcriptional analysis of inhibitor
treated cells [231] and phenotypic profiling of associated changes in the cell [232]. This can be
supported with secondary screenings across multiple species. If screening against a species that
lacks the target of interest results in significantly higher MICs, it can be assumed that the small
molecule has a specified MoA. This has been successfully applied in drug studies involving
FabI/FabL [233], which used over-expresssion and knockout mutants to discover a novel enoylACP reductase functional protein sensitive to triclosan.
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Drug discovery is a multi-step approach. Computational methods can rationally select
small-molecules, reducing associated cost and time investments of HTS empirical screening.
However, in vitro experimental screening cannot be eliminated from the process because it is
necessary to identify lead inhibitors for drug development. We previously identified more than
100 small molecules through a CBDD method and purchased 11 of the commercially available,
top-ranking compounds for further analysis. In this study, we aimed to determine the in vitro
activity of the small molecules proposed to target m-Ddh in P. gingivalis. Applying a two-step
biochemical screening approach, we used our standard enzymatic assay to evaluate targetinhibitor interaction followed by whole-cell based assays for the assessment of their
antimicrobial activity. Using biochemical screening as a complement to computational
approaches provides a comprehensive framework for the initial steps of a drug development
approach.

Materials and Methods
Bacterial Strains, plasmids and growth conditions. P. gingivalis strain W83, Prevotella
intermedia strain 17 and S. sanguinis strain SK36 were all cultured anaerobically (10% CO2,
10% H2, and 80% N2) at 37 °C in tryptic soy broth (TSB) (Becton Dickinson, Franklin Lakes,
NJ) supplemented with 1 µg/ml menadione and 5 µg/ml hemin.
Compounds. The selected small molecules were purchased from Vitas-M Laboratory, Ltd.
(Moscow, Russia), Molport (Riga, Latvia) and/or eMolecules (La Jolla, CA, USA), which
reported purities over 90%, analyzed by NMR and/or LC- MS. All compounds were resuspended in DMSO (Sigma–Aldrich, St. Louis, MO, USA) prior to use.
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Inhibitor screening and determination of IC50 values. A range of concentrations (0 - 3 mM) of
each small molecule inhibitor were added to the standard reaction and the percent of m-Ddh
enzymatic inhibition was measured by the kinetic assay previously described. Percent inhibition
was determined by the formula:

( 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛𝑛𝑜 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟 )–(𝑟𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟 )
𝑟𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛𝑛𝑜 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟

× 100. The

concentration of each inhibitor which caused 50% enzymatic inhibition (IC50) was calculated
using PRISM v6.04 software (Graphpad, San Diego, CA) from three independent experiments.
Determination of antimicrobial properties. Minimal Inhibitory Concentration (MIC) assays
were performed using a broth microdilution method [234]. P. gingivalis or P. intermedia cells
were grown overnight and the following day diluted 1/10 into fresh medium. S. sanguinis cells
were grown overnight and the following day diluted 1/100 into fresh medium. Cells were
allowed to grow to mid-log phase (OD600 ≈ 0.5). Inhibitors were serially diluted in 96-well
microtiter plates (Jet Biofil, Genesee Scientific, San Diego, CA) and an aliquot of the cell
suspension was added to each well with the inhibitor sample for a final cell count of 1×105
CFU/ml. Plates were incubated either overnight (S. sanguinis) or five days (P. gingivalis and P.
intermedia) at 37 ˚C in anaerobic conditions. The MIC was defined as the lowest concentration
of inhibitor that visually reduced cell growth relative to the controls.
Minimal bactericidal concentrations (MBC) were determined by plating bacteria from
wells of the MIC assay that showed no visible growth. Samples were plated on tryptic soy agar
plates supplemented with 5% sheep blood (Becton, Dickinson, Franklin Lakes, NJ) and
incubated at 37 ˚C in anaerobic conditions for 7 days. MBC was defined as the lowest
concentration of inhibitor that resulted in no colony formation/growth.
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Time-kill assay. P. gingivalis cells were grown overnight and the following day diluted 1/10
into fresh medium. Cells were allowed to grow to mid-log phase (OD600 ≈ 0.5) then diluted to a
final cell suspension of 1×105 CFU/ml. Inhibitors were added at a concentration of 5× the MIC
determined from the 96-well broth microdilution assay. Samples were taken at different time
intervals (0, 0.25, 0.5, 1, 2, 3, 4, 6 and 24 h) and plated on tryptic soy agar plates supplemented
with 5% sheep blood (Becton, Dickinson, Franklin Lakes, NJ) using an automated Eddy Jet
spiral plater (Neutec Group, Farmingdale, NY). Plates were incubated at 37 ˚C in anaerobic
conditions for 7 days.
SEM analysis of inhibitors exposed P. gingivalis cells. Untreated or treated P. gingivalis cells
were deposited onto a 0.1 µm disposable Millipore filter to remove medium, and samples were
fixed using 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 30 min, followed
by 1% osmium tetroxide in 0.1 M sodium cacodylate buffer (pH 7.4). Samples embedded in the
filters were then dehydrated in ethanol followed by hexamethyldisilazane (HMDS) and allowed
to air dry. The filters were sectioned and mounted onto stubs and coated with gold for three
minutes (EMS – 550 Automated Sputter Coater, Electron Microscopy Sciences, Hatfield, PA).
Micrographs were taken at 30,000× total magnification using a Zeiss EVO 50 XVP scanning
electron microscope (Carl Zeiss, Peabody, MA).
Analysis of inhibition mechanisms. Kinetic studies were carried out using the standard kinetic
assay for the oxidative deamination of m-DAP. Reactions were performed in the absence or
presence of inhibitors (0 - 0.4 mM) with varying concentrations of the substrate m-DAP or cosubstrate NADP+. The mode of inhibition and Ki was determined from non-linear regression
using PRISM v6.04 software (Graphpad, San Diego, CA) from three independent experiments.

106

The mode of inhibition was graphically visualized with Lineweaver-Burk or Hanes-Woolf plots
according to Cleland kinetics [235].

Results
Evaluation of enzymatic inhibition against m-Ddh. The initial screens for the compounds 4 14 were performed by individually adding each one to the assay solution. To identify inhibitors
with moderate to low activity, the preliminary screening was run at a concentration of 3 mM.
Enzymatic activity was measured by the standard assay described in “Materials and Methods”
and the % inhibition was calculated in comparison to the untreated enzymatic rate. This resulted
in four compounds (4, 5, 6 and 7) that displayed at least 90% inhibition of enzymatic activity.
The other compounds screened displayed 20% or less. These four compounds were then rescreened with a minimum of six concentrations to determine the IC50 value (Table 5). The IC50
values ranged between 100 M and 1 mM.
It is known that small molecules identified through large structural databases with high
IC50 values can be non-specific aggregators, sequestering the enzyme to its surface preventing
activity and causing partial denaturation [236, 237]. Aggregation-based inhibition can be
reversed through the addition of non-ionic detergents such as Triton X-100. Therefore to assess
the selectivity of our enzyme inhibitor, we re-assayed the dose-dependence with the addition of
0.01% Triton X-100, which had no effect on the normal enzymatic activity of m-Ddh. The IC50
values for 4, 5 and 6 showed no significant difference in activity (Table 5).
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Table 5. Analysis of m-Ddh enzymatic inhibition with active compounds.
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Evaluation of cellular inhibition against m-Ddh. To determine if the small-molecule inhibitors
displayed antimicrobial activity, we assessed the minimum inhibitory concentration (MIC) using
a standard broth microdilution assay. Compounds 4, 5 and 6 were tested for their ability to
visually inhibit growth of P. gingivalis cells and Erm was used as a control. Compounds 4 and 5
showed moderate antimicrobial activity with MICs of 250 M and 167 M, respectively (Table
6). With an MIC over 2 mM, compound 6 was determined not to be appropriate for whole-cell
growth inhibition. Testing of the minimum bactericidal concentration (MBC) following the MIC
assay, showed only slight differences between the MBC and MIC value (ratio of less than 4:1)
for compound 4 and 5. Compound 6 was not screened for bactericidal activity as the
concentration higher than the MIC would have been affected by the solvent concentration.
As a preliminary screen to link growth inhibition to our specific target, we first screened
the compounds against P. intermedia, another Gram-negative oral pathogen that also possesses
the target and S. sanguinis, a Gram-positive oral colonizer that does not. Comparison of the data
did indicate select growth inhibition. P. intermedia showed increased sensitivity to compound 4
but decreased sensitivity to 5. However, 4 and 5 had the greatest differences between S.
sanguinis and P. gingivalis growth inhibition. Compound 4 showed 7× MIC of P. gingivalis and
5 was more than double. Compound 6 didn’t show significant levels of inhibition similar to P.
gingivalis and P. intermedia (Table 6). Previous studies show that supplementation of m-DAP
into to the media of mutants lacking one or more of the enzyme within the m-DAP/lysine
biosynthesis pathway can allow for growth and recovery [180, 183, 238]. Thus, to further link
growth inhibition with m-Ddh inhibition, we re-assessed the MICs with the addition of the
target’s essential product m-DAP. This had no effect on the growth inhibition for 5 or 6 in P.
gingivalis, P. intermedia or S. sanguinis. However, compound 4 showed a slight increase in

109

Table 6. Analysis of whole-cell inhibition with active inhibitors
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sensitivity when 25 M of m-DAP was added to the assay for P. gingivalis and P. intermedia
(Table 6).
As MICs are static measurements, we wanted to next observe the kinetic effects the three
active inhibitors had on the growth of P. gingivalis. Cells were exposed to the compounds and
total viable cells were measured at different time intervals. At 5× MIC, compound 4 reduced the
viable P. gingivalis cell count by 2 log10 CFU /ml within 6 h of exposure. However, 5 rapidly
reduced the cell count upon treatment. After 2 h of exposure there was a 5 log10 CFU/ml
reduction, resulting in no viable cell count (Fig. 17). Cells exposed to 6 at the higher
concentration treatments were affected by the DMSO solvent and could not be assessed.
Phenotypic profiling linking target inhibition to growth effects were assessed by changes
in the cellular morphology. P. gingivalis cells exposed to either compound 4 or 5 were examined
by scanning electron micrograph (SEM). Compound 6 was left out of the analysis due to the high
MIC concentration. Treated P. gingivalis showed an alteration of the cellular structure compared
to the untreated cells (Fig. 18). Cells were visibly misshapen.
SAR evaluation of compound 4 core scaffold. From our target-based screening assay,
compound 4 displayed the most potent activity. Therefore, commercially available analogues
with 70% -90% structural similarities identified through the ZINC database were purchased and
screened for a preliminary evaluation of the core scaffold SAR. The structures and activities are
listed in Table 7. The analogues differ at two substitution sites at both ends of the structure with
IC50 ranging from 127 – 238 M. Removing the methoxy group from the R1 phenyl group of the
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Figure 17. Time-kill analysis of compound treated P. gingivalis.
P. gingivalis cells were treated with 5x the previously determined MIC for either Compound 4 (triangle)
or Compound 5 (square) and bacterial cell counts were assessed at 0, 0.25, 0.5, 1, 2, 3, 4, 6 and 24 hours.
The mean plus the standard deviation is shown for each time point from a minimum of n=3 independent
experiments. For cell counts equal to 0 CFU/mL, 1 was used for the log transformation.
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Figure 18. SEM analysis of compound treated P. gingivalis cells.
(a) Untreated cells. (b) Compound 4 treated cells at 5x the previously determined MIC concentration. (c)
Compound 5 treated cells at 5x the previously determined MIC concentration.
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Table 7. SAR of compound 4 analogues.
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original structure and replacing it with a methyl group resulted in the most potent inhibitor
screened with a slight decrease in the IC50 (compound 4a, IC50 =127 M). This may be due to a
decrease in size preventing a steric hinderance. However, adding electron withdrawing 3- or 4carboxyl or electron donating 3-hydroxyl groups on the core R2 phenyl moiety, didn’t exhibit
any significant effect on the activity. This was observed from the structures of compound 4a-4d
suggesting that substitutions are tolerated around the ring within the binding site of these
compounds. However, the addition of methyl groups to the 3- and 4- position on the R1 phenyl
moiety for 4e resulted in an increase in the IC50 (IC50 = 238 M). Comparison with between
compound 4a and 4e suggest that an additional moiety to the 3-position of the phenyl ring is less
tolerable to the intermolecular interaction.
Evaluation of inhibition mechanism. Based on our pharmacophore model and docking studies,
our three active inhibitors share a similar binding pattern within the active site, competing with
m-DAP. The intermolecular interactions are depicted in Figure 19. Hydrogen bond interactions
are represented by dashed lines. The interactions are shown to follow the proposed
pharmacophore models in that hydrogen bonding interactions between the sulfonamides are
occurring with Arg183 and Thr173. Hydrophobic stacking interactions occur between the
aromatic rings of the inhibitors and residues Phe148 and potential Trp123 of the active site.
There may also be potential hydrogen bonding between the ligands’ carboxylic groups and
residues Gly155 and Met154. In addition, for our model, the carboxylate groups form hydrogen
bonds with the backbone amide of Ser153 and Met154. Compound 4 makes an additional
hydrogen- bonding interaction with Tyr207 and - stacking interaction with Phe148, which

117

118

Figure 19. 3D analysis of binding model for active inhibitors.
Optimal binding model for Compound 4 (a), Compound 5 (b) and Compound 6 (c) are shown above. Key
residues are displayed as ball and sticks and colored corresponding to atom type. Residues labeled in the
bottom middle figure correspond to all figures. Hydrogens were omitted for clarity. Potential hydrogen
bonding interactions between m-Ddh residues and inhibitors are shown by yellow dashed lines.
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Figure 20. Inhibition mechanism of active compounds in regards to substrate, m-DAP and cosubstrate, NADP+.
(a) Compound 4 (b) Compound 5 and (c) Compound 6 inhibition mechanisms against m-DAP. (d)
Compound 4 (e) Compound 5 and (f) Compound 6 inhibition mechanisms against NADP+.
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may be one of the many reasons for its better activity. To verify this interaction, the method of
inhibition was kinetically determined. The substrate m-DAP was varied over several
concentrations of each inhibitor. The inhibition pattern for all three compounds was revealed to
be non-competitive, as there was no change in the Km and a decrease in Vmax compared to the
activity in the absence of the inhibitor (Fig. 20a-c). Due to structural similarities between the
compound scaffolds and the co-substrate and the proximity of the two binding sites, we next
examined the possibility that one of more of the inhibitors may be binding in the NADP+ binding
site. This inhibition study showed an uncompetitive inhibition pattern as there was an increase in
the Km and a decrease in Vmax compared to the enzymatic rate in the absence of the inhibitor
(Fig. 20d-f).

Discussion
In this study, we evaluated the activity of compounds identified through a CBDD method. A
two-step screening strategy was employed to assay m-Ddh specific inhibition and P. gingivalis
growth inhibition. From 11 compounds purchased and screened in vitro, three showed targetspecific inhibition with IC50 values ranging from 100-300 M. Several other compounds showed
slight activity in the higher millimolar range. The most potent compounds (4, 5 and 6) showed
limited structural similarity. The core structure of compound 4 and 6 were both sulfonyl amino
quinoxaline derivatives while 5 was a sulfonyl amino naphthalene derivative. However, all three
possessed similar functional groups and were predicted to share basic pharmacophoric features.
The three compounds possessed a sulfonamide core attached to large aromatic structures with
carboxylate functional groups. The importance of the sulfonamide has literature precedence in
the search for antimicrobials targeting lysine biosynthesis. Compounds structurally similar to our
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hits that possessed sulfonamides and sulfones were identified as fairly good inhibitors of
dihydrodipicolinate reductase, another enzyme in the lysine biosynthesis pathway [239, 240].
Based on docking studies, the sulfonamide groups were predicted to favorably interact with
Arg183 and Thr173 forming hydrogen bonds, while the aromatic moieties would create
hydrophobic interactions. From docking studies it appears the distance of the carboxylic groups
may not allow for hydrogen bonds with residues at the other end of the binding pocket. However,
based on other studies, m-Ddh exists in an open and closed conformation [218]. This would
bring the residues surrounding the compounds within the distance necessary to form stronger
hydrogen bonds. It should be noted that previous studies have reported more potent inhibitors
against m-Ddh [209, 239, 241]. However, these compounds are typically small analogous
structures, derived from the substrate m-DAP that possess few ‘drug-like’ features, making
optimization difficult [239], and suggesting little hope for selectivity. Our compounds allow for
the development of more active compounds, similar to the in silico screening against thymidylate
synthase, an enzyme is essential for DNA replication, by DesJarlais et al. [242]. The initial
computational study yielded several compounds with activity in the high micromolar range, but
following further analysis and optimization resulted in an increase in potency as well as
verification of the binding mode.
In the pursuit of a preliminary SAR analysis, 5 analogues of the most active inhibitor
(compound 4) scaffolds were screened. Through a small substitution, we identified one
compound (4a) that showed a slight increase in activity and one compound with a decrease in
activity (4e). Based on our predicted knowledge of the compound binding, comparison of the
intermolecular interaction of 4a and 4e indicate, while the binding model appears similar,
experimentally it appears the additional functional groups around the phenyl ring closer to

123

Trp123 and Phe148 within the binding pocket are not favored. On the other end, additional
groups to the phenyl ring near Thr173 and Gly155 are tolerated. Screening of an analogue with a
3-methyl addition at the R1 substitution and 3-carboxyl at the R2 substitution would allow for the
direct comparison to 4a. This would allow us to determine if the methyl group in the paraposition increases the potency and if the additional methyl group decreases potency. The addition
of a hydroxyl group or a carboxylate in the 3- or 4-position showed no significant difference in
activity. As this is a preliminary SAR study, screening analogues with increased structural
diversity or fragment-based screening based on the deconstruction of the core scaffold will
provide a more comprehensive analysis of the essential interactions.
Previous initial-velocity data [216] in m-Ddh show that the reaction proceeds through a
sequential ordered ternary-binary mechanism with NADP+ binding first, followed by the
substrate m-DAP. The product is then released, followed by NADPH. Our studies into the
mechanism of inhibition show the inhibitory compounds to be non-competitive with respect to
m-DAP, but uncompetitive with respect to NADP+. In concordance with the binding order, this
would indicate that the compounds bind to either the Enzyme-NADP+ complex or the EnzymeNADPH complex, thus potentially preventing a necessary conformational change and/or
reducing the affinity of m-DAP for the protein. This type of mechanism of inhibition could be
beneficial for future therapeutics. Treatment with an optimized inhibitor competing with m-DAP,
would result in the accumulation of the substrate within the cytosol or a regulation mechanism in
order to meet the need of the cell. An increase in the localized substrate would then need to be
balanced by high concentrations of the inhibitor. A non-competitive inhibitor, however would
not be affected by the increased concentration of substrate compared to a competitive inhibitor,
making it more effective at lower concentrations.
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One of the most difficult aspects of target-based drug discovery is identifying compounds
that show effective whole-cell activity while maintaining the key pharmacokinetics. While the
compounds identified showed potential against m-Ddh, they exhibited only slight antimicrobial
activity in P. gingivalis. Nevertheless, the potential for antimicrobial activity should not be
ignored as analogous structures and optimization of the scaffold could improve whole cell
inhibition. Several reasons could contribute to the low observed MIC values. For one, bacterial
inhibitors must be able to penetrate the cell membrane while maintaining enough soluble and
free fractions to inhibit the target at sufficient concentrations. The compound also must avoid
being expelled from the cell through efflux pumps. Another reason could be due to the
sulfonamide group present on compounds 4, 5 and 6. Sulfonamides are well known
antimicrobials that target folate biosynthesis, and bacterial cells may show a degree of drug
resistance [239]. There is also the potential for non-specific inhibition or off-target interactions.
This would result in what appears to be a variation in activity between whole-cell and target
inhibition. This was observed for compound 5 which displayed a lower MIC than IC50. While a
detailed structure-activity relationship for the antimicrobial properties cannot yet be determined
from these studies, it may be speculated that the more favorable whole-cell activity seen in
Compound 5 compared to compound 4 and 6 is due to lipophilicity. The relatively low lipophilic
nature of compound 6 (cLogP = 1.70) compared to 5 (cLogP = 3.68) may have decreased
permeability through the cellular membrane of P. gingivalis. While compound 4 displayed the
more potent target-based screening, the high lipophilic nature (cLogP =5.26) may have had a
significant effect on the solubility, reducing the efficacy during cell-based screening [243].
However, we were able to show differential activity indicating specificity. Testing in P.
gingivalis and P. intermedia, both of which possess the target, m-Dh showed a greater degree of
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growth inhibition compared to S. sanguinis, which lacks the target. Compounds tested for S.
sanguinis showed almost no antimicrobial activity (compound 4 and 6) or MICs more than
double that of those seen in P. gingivalis (compound 5). Supplementing m-DAP into the growth
media as a substrate competitor to the compounds did not correlate to an increase in MICs.
While previous studies show that supplementation of m-DAP for E. coli and M. smegatis mutants
restores growth in DAP auxotrophs [180, 238], it is not known whether P. gingivalis can
specifically uptake and utilize m-DAP for its benefit. In addition if the compounds act in a noncompetitive or irreversible manner, addition of m-DAP would not necessarily compensate for the
inhibitor activity. Analysis of the kinetic growth inhibition indicated the activity of these
compounds are time and dose dependent, with higher concentrations and longer exposure times
leading to an increased loss of cell viability. Compound 5 completely eliminated P. gingivalis
cell viability after two hours of exposure at 5x the MIC concentration, while Compound 4
maintained a low cell count after six hours of treatment. This is also consistent with the MBC
being less than 4x the MIC as antimicrobials with MBC in close range of the MIC are typically
classified as bactericidal.
In conclusion, we demonstrate the rationale for applying a focused biochemical
screening with CBDD to identify inhibitors. Our results show that by utilizing a target screen we
can select compounds which actively inhibit m-Ddh from P. gingivalis, identify the inhibition
mechanisms and assess the SAR. Coupled with whole-cell screen we can identify compounds
with antimicrobial properties and link the MoA. While the activities of these first generation
compounds are somewhat weak, continued studies into the intermolecular binding interaction
could help to discern which features are key, allowing for the improvement of novel inhibitors.
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Conclusion
The goal of this project was to introduce the beginnings of a model for antimicrobial drug
discovery using the periodontal pathogen, P. gingivalis. Accordingly, we have successfully
presented a thorough strategy. By understanding the three main biological functions for bacterial
survival, we were able to create a network of pathways connected to the synthesis of essential
metabolic components. As we demonstrated, this allowed for the accurate prediction of essential
genes as potential antibacterial targets. Additionally, we believe this protocol allows for the
comparison of alternative pathways and gene sets for species-selective targeting. Following the
selection of a target, rational computer-based drug discovery (CBDD) was applied for the rapid
and cost-effective identification of small-molecule compounds. We continued with our model to
show that analysis of the protein structure and intermolecular interactions allowed for the
utilization of a high-throughput virtual screen to select compounds with a higher probability of
demonstrating target inhibition. Finally, by developing a simple and effective screening strategy
to assess target and cell growth inhibition, we established that we could determine the in vitro
activity of selected small-molecule compounds. Through this screening, not only are compounds
with activity verified, but the mechanism of inhibition is determined and SAR studies can be
started.
The significance of our study should also be noted for our chosen model. First, we
identified m-Ddh, an essential enzyme for P. gingivalis, as a potential pathogen-specific target
within the oral cavity. The dual role of m-Ddh in protein and cell wall biosynthesis makes it an
exceptional drug target, as it would inhibit two essential biological processes. Additionally, mDdh is present within several other pathogenic colonizers, including P. intermedia, T. denticola
and T. forsythia, while absent in the majority of early oral colonizers. Since m-Ddh is a unique
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target found within a limited number of species, we theorize this would allow us to potentially
develop novel narrow-spectrum therapy for the treatment of periodontal disease by specifically
targeting key pathogens yet preserving the healthy microbiome. Second, to the best of our
knowledge, this is the first computationally motivated target-based drug discovery for this
periodontal pathogen. CBBD is a successful strategy, especially in systemic diseases [202]. By
applying CBBD we were able to identify over 100 small molecule compounds with the potential
of target-specific inhibition. Screening of the top-ranked, commercially available compounds,
resulted in a 36% hit rate. Demonstrating that a CBDD can be applied to this bacterium, we hope
this will drive new focus into drug therapies for oral diseases utilizing a rational approach. Last,
P. gingivalis and periodontal disease can be used as the starting model for rational species
selective drug discovery. As the human body is colonized by billions of microbial cells, it is
highly unlikely a bacterial infection, especially a biofilm, would be isolated into a single species.
Therefore, careful consideration of the effect therapeutic treatment has on the microbiome should
be taken, bringing into play the justification for targeted therapies. We theorized periodontal
disease and P. gingivalis would be a beneficial model as the oral microbiome is one of the most
diverse sites on the body and P. gingivalis is widely recognized as one of the major contributors
to periodontitis [32, 34, 70, 86, 244]. P. gingivalis can easily be cultured in the lab within a
reasonable amount of time, allowing for in vitro testing. Additionally, periodontal disease has
been extensively studied for years yielding suitable models for the disease, both in vitro and in
vivo [245-247].
Some challenges encountered during this study should be addressed as they may add in
the future improvement of the process. For one, it is important to verify that the target is
essential in vivo and in vitro. Essential gene studies are usually preformed under laboratory,
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nutrient-rich conditions. This does not always correspond to in vivo conditions where nutrients
may be provided by the host or alternate pathways induced through stress factors. This is
especially important for broad-spectrum targeting across multiple species. If possible, ex vivo
models can be established that more closely mimic in vivo growth conditions and gene
essentiality can be observed in various nutrient conditions. Subsequently, rational drug discovery
assays must be designed to verify target inhibition during cell-based screening. The use of WT
and mutant bacteria strains that overexpress and underexpress the target will not only identify
compounds with antibacterial properties but select for those with target-specific inhibition.
Alternatively, inducible antisense RNA could be used to control the expression level of the target
and sensitivity to different inhibitor concentrations can be gauged. The compound database
screened also needs careful consideration. Through studies by Lipinski et al., it was observed
that these inhibitors generally follow certain traits (no more than 500 Da in size, five or fewer
hydrogen bond donors, no more than 10 hydrogen bond acceptors and a logPo/w no greater than
five), known as Lipinski’s rule of five [187, 188]. However, antimicrobials do not always follow
this rule [97, 126]. Analysis of clinically approved antibiotics show that they are structurally
more complex and larger in size. They also possess more hydrogen donors and acceptors and are
more hydrophilic [97, 126]. Increased structural diversity in established chemical libraries or the
construction of dedicated databases with compounds possessing antimicrobial properties would
be beneficial. There has also been a resurgence in the search for natural compounds, similar to
those identified during the ‘golden era’ of antibiotic research [97, 248]. Combining these
compounds with a CBDD approach and other technical advances may bring new interest and
success in this field of research.
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We anticipate several directions for future studies. We first intend to continue the
evaluation of the MoA to link whole-cell activity to target inhibition. By placing m-Ddh under an
inducible promoter we can regulate the expression and screen compounds for changes in wholecell growth inhibition. A more focused SAR study is also underway through the
deconstruction/reconstruction of the three active compound inhibitors. The scaffold of the three
active compounds will be systematically broken down into core functional groups. The basic
structure of these compounds will then be re-evaluated through in silico and in vitro screening to
assess the differences in activity and potency. The compound will then be reconstructed to
include only the essential functional groups. Following an increase in target-based inhibition, the
structure can be further optimized for increased whole-cell activity. We also plan to further
evaluate the protein-compound binding. Select mutants will be made near the binding pocket of
m-Ddh that do not have a significant impact on the catalytic efficiency. Compounds will then be
re-screened against the mutants and inhibition will be measured to determine if the mutant
affected compound binding compared to WT. We also screened a relatively small number of
compounds from the results of our SBVS. Therefore, we plan to have a second round of
screening from the remaining hits to increase our pool of active compound inhibitors.
To conclude, we suggest that this method is an interdisciplinary approach whose
application has the potential to extend beyond what has been shown here. Employing a
combination of microbiologists, medicinal chemists and bioinformaticians we believe with time
this approach can flourish. Using their knowledge in the necessary fields and taking the
backbone of this project, we hope this can be applied to increasing deadly pathogens, such as M.
tuberculosis, as an alternative method in antibacterial research.
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Appendix

Supplemental Table 1. Predicted putative essential genes in P. gingivalis strain W83.
Functional
category

Pathway

KEGG
KO#

GeneID

Name

K00075

PG1342

murB

K01924

PG0581

murC

K01925

PG0578

murD

K01928

PG0576

murE

K03340

PG0806

-

K01921

PG0729

ddl

K01929

PG1106

murF

K01000

PG0577

mraY

K02563

PG0580

murG

K05366

PG0794

pbp1a

K03587

PG0575

-

K00215

PG2002

dapB

K00928

PG2189

lysC

K00133

PG0571

asd

K01714

PG2052

dapA

D-Glutamine and
D-glutamate
metabolism

K01776

PG0705

murI

D-Alanine
metabolism

K01775
K01929

KEGG Pathway

Peptidoglycan
biosynthesis
Cell envelope
(cell
membrane)

Peptidoglycan
biosynthesis

131

PG1097

alr

Protein ID
UDP-Nacetylenolpyruvoylgluc
osamine reductase
UDP-Nacetylmuramate--Lalanine ligase
UDP-Nacetylmuramoyl-Lalanyl-D-glutamate
synthetase
Mur ligase family
protein
Gfo/Idh/MocA family
oxidoreductase
D-alanyl-alanine
synthetase A
D-Ala-D-Ala adding
enzyme
phospho-Nacetylmuramoylpentapeptidetransferase
N-acetylglucosaminyl
transferase
penicillin-binding
protein 1A
penicillin-binding
protein 2
dihydrodipicolinate
reductase
aspartate kinase
aspartate-semialdehyde
dehydrogenase
dihydrodipicolinate
synthase

E

E

E

E
E
E
E

E

E
UA
E
E
E
E
E

glutamate racemase

E

putative bifunctional
UDP-Nacetylmuramoyltripeptide:D-alanyl-D-

UA

K01662

PG2217

dxs

K00099

PG1364

dxr

K00991

PG1434

ispD

K00919

PG0935

ispE

K01770

PG0028

ispF

K03526

PG0952

ispG

K03527

PG0604

ispH

Terpenoid backbone
biosynthesis

K00806

PG0190

uppS

Polysaccharide
transporter

-

PG0117

-

K00677

PG0070

lpxA

K02372

PG0071

lpxC

K02536

PG0072

lpxD

K00912

PG0638

lpxK

K02527

PG1565

-

K02517

PG2222

K00954

PG0369

K00859

PG0483

Terpenoid backbone
biosynthesis
(MEP/DOXP
pathway)

Lipopolysaccha
ride
biosynthesis

Fatty acid
biosynthesis

Lipopolysaccharide
biosynthesis

Pantothenate and
CoA biosynthesis

132

alanine ligase/alanine
racemase
1-deoxy-D-xylulose-5phosphate synthase
1-deoxy-D-xylulose 5phosphate
reductoisomerase
2-C-methyl-Derythritol 4-phosphate
cytidylyltransferase
4-diphosphocytidyl-2C-methyl-D-erythritol
kinase
2-C-methyl-Derythritol 2,4cyclodiphosphate
synthase
4-hydroxy-3methylbut-2-en-1-yl
diphosphate synthase
4-hydroxy-3methylbut-2-enyl
diphosphate reductase
undecaprenyl
pyrophosphate
synthetase
polysaccharide
transport protein
UDP-Nacetylglucosamine
acyltransferase
bifunctional UDP-3-O[3-hydroxymyristoyl]
N-acetylglucosamine
deacetylase/(3R)hydroxymyristoyl-ACP
dehydratase
UDP-3-O-[3hydroxymyristoyl]
glucosamine Nacyltransferase
tetraacyldisaccharide
4'-kinase
3-deoxy-D-mannooctulosonic-acid
transferase

E
E

E

E

E

E

UA

E
E
E

E

E

E
E

acyltransferase

E

coaD

phosphopantetheine
adenylyltransferase

E

coaE

dephospho-CoA kinase

E

Biotin metabolism

Fatty acid
biosynthesis

Glycolysis /
Gluconeogenesis
Glycerophosph
olipid /
glycerolipid
metabolism

Glycerophospholipi
d
metabolism/glycero
lipid metabolism
Glycerophospholipi
d metabolism

Energy
production

Glycolysis

Glycolysis /
Gluconeogenesis
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K03524

PG1601

birA

biotin--acetyl-CoAcarboxylase ligase

E

K02078

PG1765

acpP

acyl carrier protein

E

K00648

PG2141

fabH

K00645

PG0138

fabD

K09458

PG1764

-

K00059

PG1239

fabG

K02371

PG1416

fabK

K01803

PG0623

tpiA

K00057

PG1369

gpsA

K00980

PG2068

tagD

K00655

PG1249

plsC

K00981

PG0046

cdsA

K01810

PG1368

pgi

K01835

PG2010

pgm

K04041

PG0793

fbp

K01624

PG1755

fba

K00134

PG2124

gapA

K00927

PG1677

pgk

K01834

PG0130

gpmA

K15634

PG1513

-

K01689

PG1824

eno

K01006

PG1017

ppdk

3-oxoacyl-(acyl carrier
protein) synthase III
malonyl-CoA:ACP
transacylase,
3-oxoacyl-(acyl carrier
protein) synthase II
3-ketoacyl-(acylcarrier-protein)
reductase
enoyl-acyl carrier
protein(ACP)
reductase,
triosephosphate
isomerase
glycerol-3-phosphate
dehydrogenase
glycerol-3-phosphate
cytidylyltransferase
1-acyl-sn-glycerol-3phosphate
acyltransferase,
phosphatidate
cytidylyltransferase,
glucose-6-phosphate
isomerase
phophomannomutase
fructose-1,6bisphosphatase
fructose-bisphosphate
aldolase
glyceraldehyde 3phosphate
dehydrogenase
phosphoglycerate
kinase
2,3bisphosphoglyceratedependent
phosphoglycerate
mutase
phosphoribosyltransfera
se/phosphoglycerate
mutase
phosphopyruvate
hydratase
pyruvate phosphate
dikinase

E
E
E
UA

UA
E
E
E
UA
E
E
UA
E
E
E
E

E

E
UA
NE

Pentose
phosphate
pathway

NAD+/NADP+
biosynthesis

Pentose phosphate
pathway

Nicotinate and
nicotinamide
metabolism

Purine metabolism

Pyrimidine
metabolism
Purine
metabolism/Pyrimid
ine metabolism
Nucleotide
biosynthesis

Folate biosynthesis
Genetic
Information
inheritance

DNA repliction

DNA replication
(DNA polymerase
III)
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phosphoenolpyruvate
carboxykinase
ribose-phosphate
pyrophosphokinase
deoxyribose-phosphate
aldolase
nicotinate
phosphoribosyltransfera
se

K01610

PG1676

pckA

K00948

PG2097

prsA

K01619

PG1996

deoC

K00763

PG0057

pncB

K01950

PG0531

nadE

NAD synthetase

E

K00858

PG0629

ppnK

inorganic
polyphosphate/ATPNAD kinase

E

K00942

PG0512

gmk

guanylate kinase

E

K00939

PG0791

adk

adenylate kinase

E

K09903

PG1902

pyrH

uridylate kinase

E

K00384

PG1134

trxB

thioredoxin reductase

UA

K00560

PG2060

thyA

thymidylate synthase

E

K00945

PG0603

cmk

cytidylate kinase

E

K00525

PG1129

nrd

ribonucleotide
reductase

NE

K01495

PG0625

folE

K00950

PG1541

folK

K01633

PG2091

folB

K00796

PG1589

folP

K01930

PG0463

folC

K00287

PG2061

folA

K02343

PG1418

dnaX

K02341

PG0932

-

K02340

PG0949

-

K02342

PG1852

-

K02342

PG0223

-

K02337

PG0035

dnaE

K02338

PG1853

dnaN

GTP cyclohydrolase I
2-amino-4-hydroxy-6hydroxymethyldihydro
pteridine
pyrophosphokinase
dihydroneopterin
aldolase
dihydropteroate
synthase
dihydrofolate
synthetase
dihydrofolate reductase
DNA polymerase III
subunits gamma and tau
DNA polymerase III
subunit delta'
DNA polymerase III
subunit delta
exonuclease (DNA
polymerase III subunit
epsilon)
exonuclease (DNA
polymerase III subunit
epsilon)
DNA polymerase III
DnaE
DNA polymerase III
subunit beta

NE
E
UA
E

E
UA

E
E
UA
E
E
UA
E
E

NE
UA
E

DNA replication
proteins (Initiation
and re-initiation)

DNA replication
proteins (DNA
topoisomerase)

Homologous
recombination
(Holliday junction)

Transcription

Protein
biosynthesis

K02314

PG1242

dnaB

K02316

PG1814

dnaG

K03111

PG0271

ssb

K01972

PG1253

ligA

K02335

PG1794

polA

K02313

PG0001

dnaA

K03530

PG0121

hup-1

K03530

PG1258

hup-2

K02470

PG1702

gyrB

replicative DNA
helicase
DNA primase
single-strand DNAbinding protein
NAD-dependent DNA
ligase LigA
DNA polymerase I
chromosomal
replication initiation
protein
DNA-binding protein
HU,
DNA-binding protein
HU
DNA gyrase subunit B

K02469

PG1386

gyrA

DNA gyrase subunit A

E

K03168

PG0754

topA

E

K02622

PG0368

parE

K02621

PG1622

parC

K03551

PG0488

ruvB

K07447

PG2202

-

K03043

PG0394

rpoB

K03046

PG0395

rpoC

K03086

PG0594

rpoD

K03040

PG1911

rpoA

K02863

PG0391

rplA

K02886

PG1935

rplB

K02906

PG1938

rplC

K02926

PG1937

rplD

K02931

PG1926

rplE

K02933

PG1923

rplF

K02935

PG0393

rplL

K02864

PG0392

rplJ

DNA topoisomerase I
DNA topoisomerase IV
subunit B
DNA topoisomerase IV
subunit A
Holliday junction DNA
helicase B
Holliday junction
resolvase-like protein
DNA-directed RNA
polymerase subunit
beta
DNA-directed RNA
polymerase subunit
beta'
RNA polymerase sigma
factor RpoD
DNA-directed RNA
polymerase subunit
alpha
50S ribosomal protein
L1
50S ribosomal protein
L2
50S ribosomal protein
L3
50S ribosomal protein
L4
50S ribosomal protein
L5
50S ribosomal protein
L6
50S ribosomal protein
L7/L12
50S ribosomal protein
L10

RNA polymerase

Ribosome
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E
E
E
E
E
E
UA
E
E

E
E
E
UA
UA

E
UA
E
E
E
E
E
E
E
E
E
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K02867

PG0390

rplK

K02871

PG0375

rplM

K02874

PG1928

rplN

K02878

PG1931

rplP

K02879

PG1910

rplQ

K02881

PG1922

rplR

K02884

PG0037

rplS

K02887

PG0989

rplT

K02890

PG1933

rplV

K02892

PG1936

rplW

K02899

PG0315

rpmA

K02914

PG0656

rpmH

K02919

PG1915

rpmJ

K02916

PG0990

rpmI

K02895

PG1927

rplX

K02897

PG0167

rplY

K02876

PG1919

rplO

K02907

PG1920

rpmD

K02888

PG0314

rplU

K02904

PG1930

rpmC

K02945

PG1297

rpsA

K02967

PG0377

rpsB

K02982

PG1932

rpsC

K02986

PG1912

rpsD

K02988

PG1921

rpsE

K02990

PG0595

rpsF

K02992

PG1941

rpsG

50S ribosomal protein
L11
50S ribosomal protein
L13
50S ribosomal protein
L14
50S ribosomal protein
L16
50S ribosomal protein
L17
50S ribosomal protein
L18
50S ribosomal protein
L19
50S ribosomal protein
L20
50S ribosomal protein
L22
50S ribosomal protein
L23
50S ribosomal protein
L27
50S ribosomal protein
L34
50S ribosomal protein
L36
50S ribosomal protein
L35
50S ribosomal protein
L24
50S ribosomal protein
L25
50S ribosomal protein
L15
50S ribosomal protein
L30
50S ribosomal protein
L21
50S ribosomal protein
L29
30S ribosomal protein
S1
30S ribosomal protein
S2
30S ribosomal protein
S3
30S ribosomal protein
S4
30S ribosomal protein
S5
30S ribosomal protein
S6
30S ribosomal protein
S7

E
E
E
E
UA
E
UA
E
E
E
E
UA
E
E
E
E
E
E
E
E
UA
E
E
E
E
E
E

Aminoacyl-tRNA
biosynthesis (tRNA
synthetase)

137

K02994

PG1924

rpsH

K02946

PG1939

rpsJ

K02948

PG1913

rpsK

K02950

PG1942

rpsL

K02954

PG1925

rpsN

K02959

PG2117

rpsP

K02961

PG1929

rpsQ

K02963

PG0596

rpsR

K02965

PG1934

rpsS

K02952

PG1914

rpsM

K02956

PG1758

rpsO

K02996

PG0376

rpsI

K01875

PG0316

serS

K01874

PG0170

metG

K04567

PG1370

lysS

K01885

PG1566

gltX

K01886

PG1951

glnS

K01883

PG1878

cysS

K01887

PG0267

argS

K01867

PG2085

trpS

K01889

PG1771

pheS

K01890

PG0099

pheT

K01870

PG1596

ileS

K01881

PG0962

proS

30S ribosomal protein
S8
30S ribosomal protein
S10
30S ribosomal protein
S11
30S ribosomal protein
S12
30S ribosomal protein
S14
30S ribosomal protein
S16
30S ribosomal protein
S17
30S ribosomal protein
S18
30S ribosomal protein
S19
30S ribosomal protein
S13
30S ribosomal protein
S15
30S ribosomal protein
S9
seryl-tRNA synthetase
methionyl-tRNA
synthetase
lysyl-tRNA synthetase
glutamyl-tRNA
synthetase
glutaminyl-tRNA
synthetase
cysteinyl-tRNA
synthetase
arginyl-tRNA
synthetase
tryptophanyl-tRNA
synthetase II
phenylalanyl-tRNA
synthetase subunit
alpha
phenylalanyl-tRNA
synthetase subunit beta
isoleucyl-tRNA
synthetase
prolyl-tRNA synthetase

K01880

PG2165

glyS

glycyl-tRNA synthetase

E

K01872

PG1246

alaS

E

K01892

PG2062

hisS

K01873

PG1132

valS

K01868

PG0992

thrS

alanyl-tRNA synthetase
histidyl-tRNA
synthetase
valyl-tRNA synthetase
threonyl-tRNA
synthetase

E
E
E
E
E
E
E
E
E
E
E
E
E
UA
E
E
E
E
E
E
E
E
E
E

E
UA
E

(tRNA processing)

Translation factors
(Initiation factor)

Translation factors
(Elongation factors)
Translation factors
(Release factors)
Translation factors
(Recycling factors)

Protein export

Chaperones and
folding catalysts
(Protein folding)

138

K01866

PG0263

tyrS

K01869

PG0796

leuS

K01893

PG1121

asnC

K01876

PG0153

aspS

K00604

PG2023

fmt

K01056

PG0166

pth

K04075

PG2046

-

K00554

PG2035

trmD

K00784

PG0739

elaC

K03536

PG0201

rnpA

K00566

PG0268

mnmA

K02518

PG1916

infA

K02519

PG0255

infB

K02520

PG0991

infC

K02358

PG0387

tuf

tyrosyl-tRNA
synthetase
leucyl-tRNA synthetase
asparaginyl-tRNA
synthetase
aspartyl-tRNA
synthetase
methionyl-tRNA
formyltransferase
peptidyl-tRNA
hydrolase
hypothetical protein:
tRNA(Ile)-lysidine
synthase
tRNA (guanine-N(1)-)methyltransferase
ribonuclease Z
ribonuclease P protein
component,
tRNA-specific 2thiouridylase MnmA
translation initiation
factor IF-1
translation initiation
factor IF-2
translation initiation
factor IF-3
elongation factor Tu

K02357

PG0378

tsf

elongation factor Ts

E

K02355

PG1940

fusA

elongation factor G

E

K02355

PG0933

fusA

NE

K02835

PG0074

prfA

K02838

PG1901

frr

K03070

PG0514

secA

K12257

PG1762

secDF

K03106

PG1115

ffh

K03076

PG1918

secY

K03110

PG0151

ftsY

K04077

PG0520

groEL

elongation factor G
peptide chain release
factor 1
ribosome recycling
factor
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Supplemental Figure 1. Example of transposon insertion for P. gingivalis strain W83.
Top panel represents the transposon insertion pattern for an essential gene PG1959, rpmG 50S ribosomal
protein L33. Bottom panel represents a transposon insertion pattern for a non-essential gene PG0392, rplL
50S ribosomal protein L10. Highlighted blue bars depict the indicated gene sequence. Red arrows represent
location and orientation of a single insertion. Each gene shows insertions for two technical repeats. Courtesy
of Dr. Brian A. Klein.
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Supplemental Figure 2. SDS PAGE and gel filtration analysis of purified m-Ddh from P. gingivalis.
Samples were loaded on a 12.5% polyacrylamide SDS-PAGE gel and bands were detected by Coomassie G250 stain. (M) represents the protein standards marker (Bio-Rad) and (1-4) represent collected elution
fractions during purification. Arrow points to the expected size of m-Ddh at approximately 32 kDa. A
representative gel filtration chromatograph of purified m-Ddh in elution buffer ran on Superdex 75 column.
The native molecular mass followed with the expected peak at approximately 66 kDa similar to the protein
standard albumin. Standard 1 included cytochrome c and β-amylase, Standards 2 included carbonic
anhydrase and alcohol dehydrogenase and Standards 3 included albumin.
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